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ABSTRACT 
The effect of methionine-supplemented diet on the 
metabolism of polyunsaturated fatty acids was studied by 
comparing results of control and cysteine-supplemented 
diets in rats. Adult Sprague-Dawley rats (250-300 g) 
were fed for a period of 17 days one of the following 
diets: control, cysteine-supplemented (0.505%), and/or 
methionine-supplemented (0.625%). On the last day of 
the feeding period, the rats were administered either 
[1-14CJ arachidonic acid <AA> or C1-14CJ 
eicosapentaenoic acid (EPA) by stomach tube five hours 
before sacrificingu The cyclooxygenase activity in 
liver microsomes, the apparent Km of the fatty acyl-CoA 
synthetase in liver and brain homogenates, and the 
incorporation of polyunsaturated fatty acids into the 
phosphatidylinositol fraction of brain, heart, lung, 
spleen, and kidney tissues were analyzed. 
The cyclooxygenase activity of liver microsomes in 
rats fed the methionine-supplemented diets was 
statistically significant low compared with that in rats 
fed either the control or the cysteine-supplemented 
diets. Based upon previous observations and literature 
reports, this was presumed to be due to the increased 
liver concentration of S-Adenosyl-methionine (SAM) in 
i i i 
response to the methionine-supplemented dietary regimen . 
. However, the incorporation of polyunsaturated fatty 
acids into phosphatidylinositol fraction in tissues 
investigated was not significantly different among rats 
fed the three different diets. 
The differential incorporation of [1- 14CJ 
arachidonic acid or [1-14CJ eicosapentaenoic acid into 
various tissues was partially explained by the 
observation of the apparent Kms of fatty acyl-CoA 
synthetase in brain and liver for AA and EPA. The 
approximate five-fold increase in the apparent Kms for 
these fatty acids in liver tissue compared to brain 
tissue explained the decrease in specific activity of 
liver phosphatidylinositol compared to brain 
phosphatidylinositol. The apparent Km for AA in the 
brain was about 1.5 times higher than that for EPA, thus 
the brain fatty acyl-CoA synthetase preferred EPA as the 
substrate. Whereas in the liver, the apparent Km for AA 
was about 0.6 of that for EPA. Therefore, liver 









TABLE OF CONTENTS 
INTRODUCTION a u a • u a 
REVIEW OF LITERATURE 
Biochemical and Pharmacological 
Roles of S-Adenosyl-methionine 
Metabolism of Long Chain 



















LIST OF TABLES 
TABLE 
1. Composition of Diets 
2. Cyclooxygenase Activities in Rat Liver 
Microsomes of Control, Cysteine-
Supplemented, and Methionine-Supplemented 
F:a ts • • • • • • • 
3. The Incorporation of [1·- 14C J AA and 
[1-14CJ EPA into Phosphatidylinositol 
Fraction of Heart Tissue of Control, 
Cysteine-Supplemented, and Methionine-
Supplemented Rats •... 
4. The Incorporation of [1-14 CJ AA and 
[1-14CJ EPA into Phosphatidylinositol 
Fraction of Lung Tissue of Control, 
Cysteine-Supplemented, and Methionine-
Supplemented Rats ..•. 
5. The Incorporation of [1-14 CJ AA and 
[1-14CJ EPA into Phosphatidylinositol 
Fraction of Spleen Tissue of Control, 
Cysteine-Supplemented, and Methionine-
Supplemented Rats •••. 
6. The Incorporation ·of [1-14 CJ AA and 
[1-14CJ EPA into Phosphatidylinositol 
Fraction of Liver Mitochondria and Nuclei 
of Control, Cysteine-Supplemented, and 
Methionine-Supplemented Rats 
7. The Incorporation of [1-14 CJ AA and 
[1-14CJ EPA into Phosphatidylinositol 
Fraction of Brain Tissue of Control, 
Cysteine-Supplemented, and Methionine-
Supplemented Rats •... 
8. The Incorporation of C1-14 CJ AA and 
[1- 14CJ EPA into Phosphatidylinositol 
Fraction of Kidney Tissue of Control, 
Cysteine-Supplemented, and Methionine-





6 .., ..... 
63 
64· 
6 C' ._I 
66 
67 
LIST OF FIGUF~ES 
FIGUF:E PAGE 
1. S-Adenosylrnethionine is the Principal 
Methyl Donor in Transmethylations •• 
2. Biosynthesis of Polyamines and S-Adenosyl-
Methianine Metabolism in Mammalian 
Tissues 
3. Role of SAM in a Transmination Reaction 
4 
11 
in the Pathway of Biotin Bi osynthesi s • . 13 
4. Metabolic Relationships Among 
Transmethylation, Transsulfuration and 
the Folate Cycle • . • • . . • • • • 16 
5. A Scheme Showing the Metabolic 
Relationship between Polyunsaturated Fatty 
Acids and Membrane Phospholipids in Brain 32 
6. Pathways of Arachidonic Acid Metabolism. 36 
7. Effect of Drugs on Eicosanoid Biosynthesis 40 
8. Typical Lineweaver-Burk Plots of Acyl-CoA 
Synthetase Activity Versus Substrate 
[1- 14CJ AA Concentration for the Brain and 
Liver. 
9. Typical Lineweaver-Burk Plots of Acyl-CoA 
Synthetase Activity Versus Substrate 
[1- 14CJ ~PA Concentration for the Brain 






S-Adenosylmethionine (SAM) has been shown to have 
analgesic and anti-inflammatory properties without 
damaging the gastrointestinal mucosa in experimental 
animals. The analgesic and anti-inflammatory properties 
of SAM have been explained by its action as an inhibitor 
of cyclooxygenase, an enzyme required for the conversion 
of the long chain polyunsaturated fatty acids into a 
precursor of the biologically active prostaglandins, 
prostacyclins and thromboxanes. Aspirin is also an 
inhibitor of the cyclooxygenase enzyme. Low doses of 
aspirin have been prescribed for patients with unstable 
angina, or those who are stroke-prone, and/or those who 
are considered at risk for coronary occulusion. 
Loo and Smith (1) have shown that rats fed diets 
supplemented with methionine had a two-fold increase in 
liver SAM compared to those fed diets supplemented with 
cysteine. It is conceivable that methionine-supplemented 
diet might raise the tissue SAM concentrations to a 
sufficient level to inhibit cyclooxygenase. If 
supplemental methionine inhibited cyclooxygenase, then 
supplemental methionine could mimic the effect of 
aspirin upon the integrity of the cardiovascular 
systems. This might have implications for the protein 
1 
intake!! specifically the methionine intake!! of the 
unstable angina!! stroke-prone and/or cardiac patient. 
Therefore!! the null hypothesis (Ho) of this 
investigation is that supplemental methionine has no 
effect on the metabolism of polyunsaturated fatty acids 
through the cyclooxygenase enzyme pathway or the 
incorporation of fatty acids into tissue phospholipid. 
The test hypothesis (Ha) is that supplemental methionine 
has an effect on the metabolism of polyunsaturated fatty 
acids through the cyclooxygenase enzyme pathway or the 
incorporation of fatty acids into tissue phospholipid. 
2 
CHAPTER II 
REVIEW OF LITERATURE 
I. BIOCHEMICAL AND PHARMACOLOGICAL ROLES OF 
S-ADENOSYL-METHIONINE 
Bios~nthesis of S-Adenos~l-L-methionine 
S-Adenosyl-L-methionine (SAM, Figure 1) is 
synthesized by all living cells, and the enzyme, ATP:L-
Methionine S-Adenosyltransferase, catalyzes the 
adenosylation of methionine at the expense of adenosine 
triphosphate (ATP>. This activation is a pre-requisite 
for the transfer of a methyl group to suitable methyl 
acceptors. The stoichiometry and major features of the 




(-) S-Adenasyl-L-methionine + PPi + Pi 
Maximum activity requires rather high concentrations of 
monovalent and divalent cations. The reaction involves 
complete dephosphorylation of ATP and the nucleophilic 
transfer of the 5~-deoxyadenosyl moiety of ATP ta one cf 
the free pairs of electrons of the thioether sulfur of 
L-methioninea The final product is one of the two 
3 
O CH 3 
~ I 
C·CH·CH ·CH-S-CH 
HO' I 2 2 ® I 2/0 
NH2 ._/ 
OH OH. 
Figure 1. S-Adenosylmethionine <SAM, AdoMet, 8(5~-
deoxyadenosyl-5~)-L-methionine) is the 
principal methyl donor in transmethylations. 
Adapted from: Cantoni, G. L., 1953 (2). 
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diastereoisomeric sulfonium compounds ((~)-S-Adenosyl-L-
methionine). The two innermost phosphate groups of ATP 
give rise to inorganic pyrophosphate (PPi), whereas the 
terminal group is the source of inorganic phosphate 
( Pi > • 
Both yeast and liver adenosyltransferase 
preparations possess tripolyphosphatase activity for 
externally added tripolyphosphate <PPPi), and this 
activity is markedly and specifically stimulated by very 
low concentrations of SAM (5). One simplified 
formulation of the reaction steps is the following (6) 
E + ATP <===> E ... ATP (a) 
Met + E ATP <===> Met E ATP ( b) 
Met . . . E ATP <===> SAM ... E PPPi ( C) 
SAM ... E PPPi<===> SAM + E + PPi + Pi ( d) 
Met+ ATP<===> SAM+ PPi + Pi 
Where Met and E designate L-methionine and the enzyme, 
respectively. 
A systematic study (7) of the tissue distribution 
of adenosyltransferase indicates that this enzyme is 
most active in the liver of various mammalian species. 
This study also shows that with the exception of kidney 
and pancreas, which display relatively high activities, 
the supernatant fluids cf homogenates of other tissues 
have only 5-10 percent of the specific enzyme activity 
of the liver. 
5 
SAM plays a dual role in the control of its 
synthesis, both as an allosteric effector at low 
concentrations and as an inhibitor at higher 
concentrations (5,8). The effect of hormone and diet on 
the activity of adenasyltransferase also has been 
investigated by several researchers. Natori (9) 
explained on the basis of ethionine studies that the 
adenosyltransferase activities of the livers of female 
rats are about twice as high as those of males. The 
administration of androgen to castrated male rats 
induces a fall in enzyme level. This finding is in 
complete disagreement with other reports. Investigations 
of the influences of other hormonal factors controlling 
transferase activity indicate that the levels of liver 
transferase in rats decrease slightly following 
adrenolectomy, and that administration of 
glucocorticosteroids (but not predominantly 
mineralocortcosteroids) increases the transferase 
activity to about 1.5-2-fold of the control levels in 
both intact and adrenalectomized animals (10). 
The influence of diet on adenosyltransferase 
activity appears to be complex. lQ YlYQ, the 
concentration of methionine is probably the limiting 
factor for the synthesis of SAM. Normal tissue levels 
of L-methionine range between 50 and 80 nmoles/g wet 
tissue weight (8). Baldessarini (11) and 
6 
Salvatore et al. (12) have shown that SAM concentration 
in tissues increases after administration of methionine. 
Lombardini et al. (5) demonstrated that the rate of 
formation of SAM bears a sigmoidal relation to the 
L-methionine concentrations when ATP is saturating. 
Moreover, the liver tissue concentration of SAM in rats 
fed methionine-supplemented diets is about two-fold 
that of rats fed diets supplemented with cysteine (1). 
The decrease in liver SAM in rats fed the cysteine-
supplemented diet appears to reflect a non-competitive 
inhibition of methionine adenosyltransferase by 
cysteine. 
Metabolic Functions of SAM 
SAM is a high energy sulfonium compound. Cantoni 
(13) has pointed out that in fact all of the three 
constituents on the sulfonium pole of SAM are 
energetically equivalent, and these properties give the 
SAM molecule its unique versatility. Recognition of the 
number of enzymatic reactions in which it functions 
either as a · substrate or as a modulator has 
significantly increased in recent years. The important 
biological . roles of SAM include transmethylation 
reactions and polyamines biosynthesisn 
7 
Transmethylatian Reactions 
Transmethylatian is considered ta be the earliest 
example of biochemical group transfer and represents by 
far the largest and most widely studied group of alkyl 
transfer reactions (14). The chemical variety of 
acceptors of a methyl group from SAM is unusually 
high. The attachment of the methyl group to the nitrogen 
atom is perhaps the most extensively studied reactions, 
but sulfur, oxygen and carbon are also other acceptors 
with binding sites. 
Bacterial chemotaxis is related to methyl 
esterificatian of membrane protein, which, in turn, 
affects response to chemoattractants (15,16). In 
mammalian systems, such as neutrophils which possess 
chemotactic responsiveness, methyl esterification plays 
a critical role as a signal far leukocyte motion (17). 
The enzymatic esterification by methylation neutralizes 
the negative charge of the carbaxyl groups of protein. 
Such neutralization of charge can alter the conformation 
of membrane proteins and thus initiate events leading to 
chemataxis of leukocytes. Hirata and Axelrod (18) 
demonstrated the methylatian of membrane phospholipids 
to elicit receptor-mediated signals through the 
membranes of a variety of cells. As the membrane 
phospholipids are successively methylated, they are 
translocated from the inside ta the outside of the 
8 
membrane!' resulting in the reduction of membrane 
viscosity. This is the mechanism and an initial common 
pathway by which specific biochemical messages, such as 
neurotransmitters, peptide hormones, lectin, and 
immunoglobulin ligands, are recognized by and bound to 
specific receptor macromolecules on the outer surface of 
cell membranes (18). 
Methylation of nucleic acids at various base and 
sugar moieties appears to be involved in a variety of 
biological regulatory mechanisms. Kawarada and Okahara 
(19) demonstrated that ?-methyl guanine residues of a 
single-stranded structure of methylated DNA, which is 
immunogenic or antigenic, play an important role in 
forming a characteristic structure required for the 
manifestation of the specific antigenicity. 
l.11 Y.lti:.9.., the binding of a carcinogen, 3-N,N·-
acetoxyacetyl amino-4,6-dimethyldipyrido-[1,2-a:3',2'-d] 
imidazole, to guanine residues of a native DNA may block 
the movement of DNA-(cytosine-5-) methyltransferase 
along the helix and thereby cause hypomethylation (20). 
This event could have significance in gene activity, 
cellular differentiation~ and cancer induction. 
9 
Polyamines Biosynthesis and Unusual Biochemical 
Roles of SAM 
Recognition of the central role of SAM as a 
precursor of polyamines was provided by the pioneering 
studies of Tabor, Rosenthal and Tabor (21). In the 
biosynthesis of polyamines recognized so far, 
decarboxylated SAM is the only biological donor of the 
propylamine moiety. The connections between the 
metabolic pathways involving SAM in mammalian tissues is 
demonstrated in Figure 2 (22). Putrescine plays a 
central role in the overall regulation, since the 
diamine activates SAM decarboxylase and in turn inhibits 
ornithine decarboxylase and spermine synthetase (22). 
The inhibitory effect of decarboxylated SAM on methyl 
transfer reactions suggests that in cellular metabolism 
SAM decarboxylase not only competes with 
methyltransferases for the same substrate, but also 
indirectly inhibits this class of reactions. 
The transfer of the unmodified amino acid side 
chain of SAM to the uridine nitrogen of tRNA represents 
one of the proposed nucleoside hypermodifications 
occurring in the maturation of tRNA (23). The modified 
uridine, i.e., 3-(3-amino-3-carboxypropyl)-uridine, has 
been detected in bacterial and mammalian tRNA, and 
10 
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Figure 2. Biosynthesis of polvamines ands~ 
adenosylmethionine metabolism in mammalian 
tissues. decaAM, S-adenosyl-(5')-3-
methylthiopropylamine; MTA, 5'-methylthio-
adenosine; AH, S-adenosylhomocysteine. 
Adapted from: Zappia, V., et al., 1977, (22). 
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its biological significance is probably related to the 
stabilization of the three-dimensional structure of the 
polynucleotide (24). 
In~~ ~Qll SAM participates in a transamination 
reaction in the biotin biosynthesis pathway (25,26). 
The reaction, catalyzed by diaminopelargonic acid 
aminotransferase, is illustrated in Figure 3. The enzyme 
requires the sulfonium ion of SAM for activity but not 
for binding to the enzyme and appears to be highly 
specific for SAM. The analogs of SAM are unable to 
transaminate with 7-keto-8-aminopelargonic acid (26). 
Recognition of the number of reactions that SAM 
exerts a regulatory role, either as an activator or as 
an inhibitor, has significantly increased in the past 
few years. SAM is an activator in vitamin B12-dependent 
methionine biosynthesis in microbial systems 
Chomocysteine remethylation in mammalian systems) (27). 
Inactive B12-dependent 1\5-methyltetrahydrofolate·-
homocysteine methyltransferase is first primed or 
activated by B 12-cobalt methylation. This priming 
requires both SAM and reduced flavoprotein. Once the 
enzyme has been converted to one of its functional forms 
by SAM methylation, it should catalyze the reaction 
which remethylates L-homocysteine to L-methionine (27). 
Conversion of the inactive form of pyruvate 











Figure 3. Role of SAM in a transamination reaction in 
the pathway of biotin biosynthesis. Adapt ed 
from: Stoner & Eisenberg, 1975 (26). 
fR /3 
g~ ~9!i and other bacteria also requires SAM~ reduced 
flavodoxin~ and the Fe-dependent protein (28). It is 
found that SAM is reductively processed during 
activation of PFL to yield methionine, adenine and 5~-
deoxyribose. Researchers (28) propose that 
rearrangements in the protein structure of PFL are 
involved in the interconversion of the two enzyme forms. 
In the active form of PFL~ the protein might be under 
conformational strain which would provide a rationale 
for the apparent spontaneity of its conversion to the 
inactive form of this enzyme. Using SAM to redistribute 
a disulfide bond and SH-group(s), for example, would be 
a feasible rearrangement process. 
Jencks and Matthews (29) demonstrated that SAM 
allosterically inhibits pig liver methylene 
tetrahydrofolate reductase. They suggest there is 
more than one binding site for SAM at each subunit of 
the reductase~ and NADPH counteracts the inhibition by 
SAM. The same mechanism has been proposed to explain the 
irreversible inactivation of calf thymus ribonuclease H 
exerted by SAM (30). 
The biological roles of this compound are 
summarized as follows: 
* Donor of methyl groups in a wide variety of 
transmethylation reactions (14>; 
14 
* Required for bacterial chemotaxis~ leukocyte 
motion!' and receptor-mediated signals 
(15!116!117, 18); 
* Required in the restriction and modification 
system of DNA in prokaryotes and eukaryotes 
< 19 !I 20) ; 
* Donor of propylarnine moiety!' after 
decarboxylation!I in the biosynthesis of 
sperrnidine!I syrn-nor-spermidine, sperrnine and sym-
nor-spermine (21,22); 
* Donor of the aminobutyryl side chain to tRNA 
(23!1 24); 
* Donor of the side chain amino group in 
biotin biosynthesis (25,26); 
* Activator of N5-methyltetrahydrofolate-
homocysteine methyltransferase and pyruvate-
formate-lyase (27,28); and 
* Inhibitor of methylene tetrahydrofolate 
reductase and ribonuclease H (29!130). 
Metabolic Pathwa~s Related to SAM 
The metabolic pathways which involve SAM are shown 
in Figure 4, i.e.!' transmethylation, transsulfuration 
and the folate cycle. Via transmethylation, SAM is 
converted into S-adenosyl-L-homocysteine (SAH), which is 
a potent inhibitor of most methyltransfering enzymes 
15 
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Figure 4. Metabolic relationships among 
transmethylation, transsulfuration and · the 
folate cycle. Adapted from: Mudd & Cantoni, 
1964 (6). 
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(31). SAH is further cleaved to adenosine and 
L-homocysteine by a specific hydrolase (8). Adenosine 
is effectively deaminated and further metabolized to 
uric acid (32), and homocysteine is metabolized by two 
competing systems. These are the trans-sulfuration 
pathways leading to cysteine, the major route for 
methionine catabolism!I and the proposed "sulfur 
conservation cycle" and connecting with the folate 
pathway. Mammalian livers contain a sensitive 
regulatory mechanism which allows either conservation or 
catabolism of methionine as a function of the dietary 
content of this nutrient (33). 
Pharmacolo,gical Effects of SAM 
SAM has been the subject of many experimental and 
clinical investigations because of its diverse 
functions. The pharmacological properties of SAM most 
e~·~tensively studied in recent years include: (a) effects 
of SAM on the central nervous system function; (b) 
effects of SAM as a detoxicant and cytoprotective 
agent in the treatment of liver disease; and (c) effects 
of SAM as an anti-inflammatory agent. 
Effects on Central Nervous System. 
In the central nervous system, SAM-dependent 
methylation processes are of particular importance in 
the biosynthesis and inactivation of neurotransmitters 
17 
and hormonally active biogenic amines. For example, both 
the formation .of melatonin and the inactivation of 
catecholamines involve 0-methylation processes, whereas 
the synthesis of adrenaline and the inactivation of 
histamine involve N-methylation reactions. In all cases 
SAM is the methyl donor. 
For many years, there has been considerable 
interest in the chemistry and pharmacology of biological 
transmethylation in the field of neuropsychiatry (34). 
This interest was largely stimulated by the fact that 
many natural or synthetic psychotropic substances are 
methylated amines. A hallucinogen, dimethyltryptamine 
(DMT>, is synthesized by a "non-specific N-methyl 
transferase'' in the brain and several other tissues; 
tryptophan, tryptamine, or N-methyltryptamine (NMT) 
could serve as a substrate for this methylating enzyme 
(35). In one study (35) the ability of human platelets 
to form DMT from NMT enzymatically tended to be highest 
in schizophrenic subjects, compared to non-schizophrenic 
subjects. This elevated enzyme activity was due to 
a reduced amount of normally occurring enzyme inhibitor 
in schizophrenics. In ~ddition, Andreoli and Maffei 
(36) reported that blood SAM levels are decreased in 
acute schizophrenia, but not in chronic schizophrenia. 
The hypothesis that depression is due to a 
metabolic disorder involving catecholamines, serotonin 
18 
or, most likely, their functional balance, supports the 
use of a variety of therapeutic agents, such as SAM. It 
has been observed that depressed patients have reduced 
catechol 0-methyltransferase (COMT) activity in 
red cells (37). This might indicate a decrease of the 
concentration of SAM as a methyl donor. 
Stramentinoli et al. (38) administered SAM to 
male Sprague-Dawley rats and determined the level of 5-
hydroxytryptamine and 5-hydroxyindolacetic acid 
(metabolites of serotonin) in the brainstem and 
forebrain. The results (38) indicated that SAM 
administration induces a significant increase in the 
levels of both metabolites in the forebrain, but only a 
slight increase (not a statistically significant 
increase) in the brainstem. These results were 
confirmed by additional experiments using depressed 
patients (39). Another clinical trial with a small 
number of patients was also performed by Scarzella (40). 
Preliminary data indicate that SAM exerts an 
antidepressant effect which is detectable after the 
first week~ and no side effects have been observed 
except for occasional and mild symptoms of anxiety. 
The effects of SAM on dopaminergic and 8-
adrenergic receptor systems were studied in aging rats 
(41). Earlier investigations demonstrated that membrane 
fluidity and receptor properties could be altered by the 
19 
degree of methylation of the membrane phospholipid (42). 
The viscosity of the striatal membranes in aging rats 
was significantly higher than in young rats, thereby 
affecting the receptor binding activity and the signal 
transmission for intracellular responses. The decrease 
in B-adrenergic binding sites induced by aging was 
antagonized by administration of SAM, suggesting that a 
deficit in this brain area of aging an~mals can be 
reversed by episodic treatment with this particular 
drU(_:J. 
SAM concentration may be depleted by some drugs, 
such as L-dopa. L-dopa is used to treat Parkinson's 
disease and acts as methyl group acceptor (43). 
Chalmers et al. (44) demonstrated that acute L-dopa 
administration to rats intracisternally injected with 
t3HJ norepinephrine caused a depletion of brain SAM as 
well as a reduction in 0-methylated [3HJ norepinephrine 
derivatives. This could directly or indirectly 
influence the normal functioning of certain neuronal 
systems. Stramentinoli and his associates (45) have 
shown that exogenous administration of SAM with L-dopa 
was not enough to compensate completely for the reduced 
concentration of SAM in the brain, but exogenous SAM 
could reverse the effect of L-dopa by a 63 percent 
increase of endogenous SAM. 
20 
Treatment of Liver Diseases with SAM --------- -- ----- -------- ---- ---
SAM has proved to be a methyl donor as well as a 
precursor of endogenous sulfurated products, and in 
particular of glutathione (GSH). Owing to these 
properties, SAM has been found to be a valuable 
therapeutic tool in the treatment of liver diseases as 
an antisteatosic, antinecrotic, detoxicant, and 
cytoprotective agent. 
The antisteatosic effect of SAM has been 
demonstrated in both ethanol-intoxicated mice and rats 
(46,47) and in humans with alcoholic liver diseases 
(48,49). Although the mechanism by which SAM 
antagonizes alcoholic fatty liver degeneration is still 
unknown, several lines of evidence have been reported. 
An acute ethanol-intoxicted mice, the 
administration of SAM reversed the effect of ethanol on 
hepatic GSH concentration and r-aminolevulinic acid 
dehydratase (ALA-D) activity. ALA-D has been 
demonstrated to require reduced sulfhydryl groups for 
its activity (46). SAM, via transsulfuration reactions, 
is a better precursor of GSH than methionine, has an 
extremely low toxicity, and is easily available as a 
pharmaceutical preparation (51). 
Feo et al. (47) demonstrated that SAM~s protective 
effect in liver steatosis, caused by chronic ethanol 
ingestion, was through inhibition of alcohol 
21 
dehydrogenase activity. Approximately 30 percent of the 
dehydrogenase activity was inhibited in both normal rats 
and those subjected to acute ethanol toxicity. This 
decrease in activity was not observed in the microsomal 
ethanol oxidizing systems of normal or intoxicated rats. 
Moreover, SAM treatment almost completely reconstituted 
the liver GSH pool and caused a large decrease in the 
liver and blood acetaldehyde contents. The Feo group 
(47) proposed that SAM~s antisteatosic effect largely 
depended on its role as a modulator of the GSH liver 
content. 
A preliminary clinical trial with SAM was conducted 
by Feaccadori et al. (48). This trial evaluated effects 
of long-term (six months) administration of SAM on 
eleven out-patients with alcoholic liver disease. Liver 
biopsy specimens of these patients showed a significant 
regression of steatosis after treatment with SAM. They 
reported that the antagonistic action of SAM against 
alcoholic fatty liver could be related to its capability 
to methylate phospholipids involved in lipoprotein 
metabolism. 
Furthermore, Micali et al. (49) investigated the 
administration of SAM in chronic liver diseases in a 
double blind controlled study. Patients treated with 
SAM showed statistically significant improvement in 
Bromosulfophthalein (BSP) clearance, liver biopsy, and 
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other biochemical parameters. These results (49) 
suggest that SAM possesses a membrane-stabilizing action 
secondary to its primary role in the phospholipid 
metabolism of membranes. This stabilizing action 
accounts for an improvement in the capture and/or 
conjugation of the dye-stuff <BSP). Also, the formation 
of endogenous SAM is influenced by the availability of 
ATP, which is reduced in steatosis (52). Exogenous SAM 
helps spare energy for the formation of SAM. Thus, 
hepatocyte lipid deposition could be removed by SAM 
intervening in the phospholipid methylation in the 
endoplasmic reticulum of the liver cell (49). 
Histological findings (49) indicate that steatosis is 
noticeably influenced by SAM through methylation of 
phosphatidylethanolamine to increase phosphatidylcholine 
synthesis. This phospholipid is capable of enhancing 
the formation of lipoproteins which could remove the 
excessive triglyceride, thereby preventing fatty liver 
from becoming extended as large fat droplets (49). 
Micali et al. also found that treatment with SAM could 
affect the metabolism of neurotransmitters, thereby 
causing significant improvements in the symptom complex 
of liver disease patients with hyperammonemia 
encephalopathy. 
SAM has been shown to protect the liver of mice 
from injuries produced by hepatotoxic agents, such as 
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large doses of acetaminophen (54). The hepatotoxicity of 
acetaminophen is related to its F'450 mediated metabolism 
to a reactive intermediate (55). Glutathione, through an 
attack of its nucleophilic sulfur atom, binds to 
reactive metabolite giving a readily eliminative 
conjugate (55). After doses of acetaminophen that 
exceed the available glutathione, binding of this 
reactive intermediate to liver proteins occurs, and is 
accompanied by liver necrosis. In one study (54) SAM 
treatment did not prevent the fall of liver glutathione 
concentrations, caused by large doses of acetaminophen. 
Histologic observations revealed that the hepatocellular 
damage was confined to a small area. The pc>ssi bi l i ty 
was considered that SAM may influence protein binding of 
the metabolite. Actually, decreased binding was 
observed in animals given SAM in addition to 
3H-acetaminophen (54). On the other hand, SAM failed to 
act on binding in i.lJ.. ~:Lti:..12. e~-: per i ment s at a 
concentration at which cysteamine almost completely 
inhibited protein binding (54). The researchers (54) 
suggested that the decreased protein binding observed ln 
YiY9 might depend on the formation of a nucleophilic 
metabolite of SAM, which was capable of binding to the 
reactive acetaminophen derivative and thus favored its 
elimination. 
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SAM is also beneficial in the treatment of lead 
intoxication (51,56). The effect of SAM administration 
on rats that received both acute and chronic lead 
exposure was demonstrated by Paredes et al. (51). 
Reduced GSH concentrations in blood and liver of 
intoxicated animals were reversed after SAM 
administration, presumably due to the role of SAM as a 
precursor of GSH (51). Moreover, reduced sulfhydryl 
groups are essential for the activity of ALA-D, a zinc 
metalloenzyme. Zinc also prevents oxidation of those 
sulfhydryl residues (50). Lead easily displaces zinc and 
blocks the active site by bridging two vicinal SH 
groups, inhibiting the enzyme. ·In one study (51> a 
significant recovery of tissue ALA-D activity, initially 
reduced in poisoned animals, was clearly produced after 
SAM treatment. This result supported the axiom that an 
enhancement of thiol content as a result of SAM 
administration facilitates the detoxication process and 
lead removal, consequently reversing the inactivation of 
the enzyme. Because of the important function of SAM in 
the central nervous system and its direct involvement in 
catecholamine metabolism (22), the authors suggested 
that effects of SAM, unrelated to GSH, on lead 
neuropathy can not be excluded (51). 
Prevention of ethynylestradiol (EE)-induced 
cholestasis by SAM was demonstrated in both rats and 
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humans (57,58,59,60). Ethynylestradiol, an estrogenic 
factor of many "combination" oral contraceptives, has 
been demonstrated to impair bile secretion and decrease 
liver plasma membrane fluidity in several animal species 
including humans, so that bile becomes supersaturated 
with cholesterol and its flow is reduced (61). Results 
of experimental investigations (57,58,62,63) indicate 
that SAM can: (a) reverse both cholestasis and related 
abnormalities of biliary lipids; (b) modify the pattern 
but not the total amount of biliary EE excretion; and 
(c) reduce the irreversible binding of estrogen to rat 
liver microsomes, probably favoring EE biotransformation 
into its methyl-derivatives in the presence of catechol-
0-methyltransferase (62,63). 
Schreiber et al. (58) suggested that another 
explanation for SAM~s anti-lithogenic effect may be its 
stimulation of phosphatidylcholine synthesis, resulting 
in an increased hepatic Na+/K+ ATPase activity and liver 
plasma membrane fluidity (18). The regulation of 
phosphatidylcholine turnover by SAM may be useful in 
hepatic cytoprotection. Clinical investigation (59) 
with non-obese subjects showed that SAM prevents EE-
induced bile lipid changes without interfering with EE 
kinetics. The researchers concluded that SAM can be 
considered an adjuvant to chronic estrogen therapy in 
subjects at the risk of developing lithogenic bile. 
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Frezza et al. (60) further investigated SAM-induced 
reversal of cholestasis of hypersensitive pregnant 
patients due to the striking estrogen increase in late 
pregnancy. The result (60) suggested that SAM decreases 
some markers of cholestasis elevated in pregnancy 
without affecting placental growth. 
Anti-inflammatory Effect of SAM 
The anti-inflammatory and analgesic properties of 
SAM in experimental animals (64,65) and its therapeutic 
action on symptoms of degenerative arthropathies (66~67) 
were reported by Italian researchers. 
Gualano et al. (64) evaluated the effect of SAM on 
carrageenin-induced edema in rats and writhings provoked 
in mice by phenylquinone and acetic acid. The data 
indicated that SAM prevents the swelling process induced 
by the above treatments in a dose-dependent manner. 
These researchers (64) also demonstrated that SAM 
inhibits the formation o·f prostaglandin E2-like material 
in the exudate produced by subcutaneous implantation of 
sterile sponges in the rat. When the ability of 
histamine to activate arachidonic acid metabolism in 
perfused guinea-pig lungs treated with SAM were studied, 
the appearance in the pulmonary effluent of TXA2-like 
material was significantly impaired (64). These results 
implied that SAM affects, by the inhibition of 
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cyclooxygenase, the activation of the endogenous 
eicosanoid system promoted by histamine. This experiment 
with arachidonic acid suggests that, as in the case of 
Indomethacin, SAM may affect pulmonary cyclo-oxygenase 
activity or other steps involved in TXA2-like material 
formation. 
Gualano and his associates (65) further 
demonstrated that oral and injected SAM in rats had 
similar effects upon the production of prostaglandin-
like material in sponge exudates and by rat peritoneal 
leukocytes during bacterial phagocytosis. The authors 
confirmed that SAM is able to interfere with arachidonic 
acid metabolism through the cyclooxygenase metabolite 
pathway (38,65). 
The therapeutic effectiveness and tolerance of SAM 
given orally to two groups of patients with hip, knee 
and vertebral arthroses and osteoarthritis were studied, 
respectively, by Capretto et al. (66) and Marcolongl et 
al. ( 67) • Results were compared with those obtained in 
a similar number of patients treated with Ibuprofen, a 
non-steroidal anti-inflammatory agent largely used for 
the symptomatic treatment of inflammatory conditions. 
Both studies (66,67) confirmed the effectiveness of SAM 
in the treatment of degenerative joint diseases. SAM 
is not only specifically capable of relieving painful 
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Joint conditions, but also excellently tolerated, 
particularly in the gastro-intestinal tract. 
II. METABOLISM OF LONG CHAIN POLYUNSATURATED 
FATTY ACIDS 
It was not until 1929 that Burr and Burr (68) 
discovered that polyunsaturated fatty acids are 
essential for the growth and normal function of all 
tissues. These fatty acids can be classified into 
three categories on the basis of their biosynthetic 
precursors: ( 1) the oleate (W-9) !I (2) the 1 inoleate 
(W-6) !I and (3) the 1 inolenate (W-3) series (69). These 
parent essential fatty acids undergo chain elongation 
and desaturation to obtain various long chain 
polyunsaturated fatty acids, such as arachidonic acid 
(c20:4)!1 eicosapentaenoic acid (c20:5)!1 and 
docosahexaenoic acid (c22:5). In mammalian tissues, the 
double bond nearest the methyl end of the chain is not 
altered when new double bonds are inserted toward the 
carboxyl terminal!' and the various fatty acids in the 
three categories are not interchangeable metabolically. 
Some of the polyunsaturated fatty acids may be converted 
to physiologically potent metabolites, but others are 
not (70,71>; some fatty acids may even inhibit the 
conversion of precursor acids to corresponding 
metabolites (72!173). Consequently!' the relative 
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proportions of precursor and inhibitor acids at the 
2-position of phospholipids may have an important 
influence upon cellular physiology. 
The lncoreoration of Pol~unsaturated Fatt~ Acids into 
Cellular PhosQ.holiQ.ids. 
The incorporation of polyunsaturated fatty acids 
into the 2-position of phospholipids is catalyzed 
sequentially by acyl CoA synthetase, then by 
acyltransferase systems into various forms of 
phospholipids. The selectivities of the acyltransferase 
systems have been determined in the presence of mixtures 
of acyl donors and suboptimal concentrations of 
acceptors (74,75,76). Lands et al. (77) demonstr~ted 
that rat liver has a high selectivity for 
polyunsaturated acids, but does not discriminate 
among the polyunsaturated acids of the W-6 and W-3 
series. The phospholipid composition in fully functional 
membrane is highly specific and complex. The acyl groups 
in phospholipids could affect membrane function in one 
or more of four ways: (1) effects on lipid fluidity; (2) 
effects on membrane thickness; (3) effects on Ii pi d 
phase; and (4) effects of specific interaction with 
membrane proteins (78). 
Arachidonic acid CAA>, rich in the Western diet, is 
preferentially incorporated into diacyl-
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glycerophosphoinositols CGPI> and diacyl-
glycerophosphocholines CGPC> (79). These membrane 
phospholipids act as a depository of arachidonic acid 
for eicosanoid synthesis, and phosphatidylinositols are 
important for signalling specific cellular activity 
(78). In general, turnover of arachidonoyl-GPI in the 
brain membranes is more rapid than other types of 
phosphoglycerides (80). This phenomenon is probably due 
to the presence of enzymes specific for metabolizing the 
gl ycerophosphoi nosi tol. llJ.. 't.:Lt.r:..Q. eNperi ments (81 > have 
shown that two types of cyclic events are related to 
metabolism of brain fatty acids: (1) the ATP-dependent 
activation of fatty acids to their acyl CoA via the acyl 
CoA synthetase, and subsequent hydrolysis of acyl CoA by 
acyl CoA hydrolase<s>; and (2) the release of 
polyunsaturated fatty acids from membrane 
phosphoglycerides via phospholipase A2 and subsequent 
reacylation of the lysophosphoglycerides by the 
acyltransferases. The polyunsaturated fatty acid level 
in brain may be regulated by enzymes responsible for 
both cyclic events (Figure 5). 
Eicosapentaenoic acid (c20:5, EPA> is a ~-3 
polyunsaturated fatty acid found in marine foods. ln 
YiYQ EPA is readily incorporated into tissue lipids (82) 
and, at the same time~ there is a reduction in their AA 




















Figure 5. A scheme showing the metabolic relationship 
between polyunsaturated fatty acids and 
membrane phospholipids in brain. Adapted from: 
Sun, G. Y., et al., 1979 (81). 
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fatty acids and demonstrated a reciprocal replacement of 
the~ - 6 by the~-3 fatty acids in brain phospholipids 
(83). This finding is in agreement with reports of 
altered fatty acid composition in membrane 
phospholipids following changes in dietary fat source 
and changes in 4J-6/IJ-3 fatty acid ratios in the 
postweanling rat (84-87) It also provides further 
evidence that fatty acid composition of membrane 
phospholipids can be altered by dietary fatty acid 
levels after the major period of brain growth and 
development in rats. 
The consumption by human subjects of diets 
containing fish or supplemented with fish oil for one to 
11 weeks produces an elevation in the percentage of EPA 
in fatty acids of platelet phospholipids (82~88-92). 
However, the biochemical mechanisms by which dietary 
fish oil and a derived W-3 fatty acid concentrate 
produce elevations in ~-3 polyunsaturated fatty acid and 
suppressW-6 polyunsaturated fatty acid in individual 
phospholipids remains unknown. The dietary effects on 
fatty acid desaturation, availability of various acyl 
coenzyme A esters in the cellular pool, and involvement 
of deacylation-reacylation reactions are the possible 
mechanisms. 
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Biologicall~ B£tiY~ Metabolites gf Pol~unsaturated 
Fatty Acids. 
One of the roles of polyunsaturated fatty acids 
is to act as precursors of prostaglandins and related 
substances, generally referred to as prostanoids (93). 
Prostanoids are made from ~atty acid precursors such as 
arachidonic acid and are a family of chemically related 
compounds comprised of prostaglandins, thromboxanes, and 
prostacyclins. Mammalian tissues are able to synthesize 
up to 20 separate prostanoids, each with subtly 
different biological activity. Leukotrienes, another 
family of biologically active substances, are 
synthesized from the same precursors as prostanoids, but 
are structurally different from prostanoids. The 
collective name for prostanoids and leukotrienes is 
eicosanoids. 
Arachidonic acid and the other prostaglandin 
precursors are not normally found in the free state in 
cells, but occur bound at 2-position of phospholipids. 
Lands and Samuelsson (94) demonstrated that the release 
of precursor acids from phospholipids must occur 
before the formation of eicosanoids. This is the primary 
rate-limiting step in the synthesis of these active 
metabolites. 
Phosphatidylcholine and phosphatidylethanolamine 
have been known to incorporate polyunsaturated fatty 
34 
acids at c-2 of the glycerol moiety, and are favored as 
sources of prostaglandin precursors through the action 
of a phosphol i pase A2 (93). However, the 1 ong--known 
"Inositol effect," iae., the rapid turnover of 
phosphatidylinositides in cells and tissues after a 
variety of stimuli (95,96), called attention to 
phosphoinosites as a possible source of the 
polyunsaturated fatty acid used in prostaglandin 
biosynthesis (97). 
In response to various stimuli (mechanical, 
hormonal, and coagulation factors) arachidonic acid is 
released from cell phospholipids by the action of 
phospholipases (Figure 6) (98). It is subsequently 
reacylated back into the phospholipids or is metabolized 
via the cyclooxygenase and/or lipoxygenases pathways to 
the eicosanoids characteristic of the given type of cell 
and biological response (98). The first pathway involves 
the enzyme cyclooxygenase, which oxygenates arachidonic 
acid to the prostag 1 and in endopero:d des-·-PGG2 and PGH2. 
These endoperoxides are then converted to the various 
prostaglandins, thromboxanes, and prostacyclinsa 
Cells like platelets contain both cyclooxygenase 
and 12-and 15-lipoxygenases. The most important platelet 
cyclooxygenase product, derived from AA, is thromboxane 
A2 (TXA2> (Figure 6). Thromboxane synthetase in 
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Figure 6. Pathways of arachidonic acid metabolism. 
Adapted from: Cannon, P. J., 1984 ( gg). 
vasoconstrictor. TXA2 also promotes platelet ~ctivation 
and release of their granular contents: adenosine 
diphosphate, serotonin, and platelet derived growth 
factor. However~ thromboxane A3 (TXA3), which is 
synthesized from EPA, is far less proaggregatory than 
TXA2 and is a weak vasoconstrictor (98). 
Vascular endothelial cells synthesize a series of 
vasodilatory prostaglandins, particularly prostacyclin 
<PGI2) (99). These cells have receptors for angiotensin 
II, bradykinin, histamine, and thrombin. All of the 
above substances activate phospholipases and release 
arachidonate to cyclooxygenase for conversion to the 
endoperoxides. PG~~ is further converted in endothelial 
cells to PGI2 by prostacyclin synthetase (Figure 6). 
PGI 2 , the major arachidonic acid product of endothelial 
cells, is a potent vasodilator of the coronary and other 
vascular beds; it also inhibits platelet aggregation by 
stimulating adenylate cyclase and elevating platelet 
levels of cyclic adenosine monophosphate (cAMP) (98). 
Dietary EPA is transformed lQ ~l~~ to prostacyclin I 3 
(PGI 3 ), which is as active as the vasodilatory and 
antiaggregatory PGI 2 (100~101) Thus its actions are 
opposite to those of TXA2. Endothelial cells synthesize 
lesser amounts of PGE2 , also a vasodilator, and PGF2x , 
which promotes venoconstriction (98). 
37 
The second pathway of arachidonic acid metabolism 
involves lipoxygenases that attack the various double 
bonds and form several unstable compounds known as 
hydroperoxy-arachidonic acids. Recently, Samuelsson 
(102) identified the products of arachidonate metabolism 
by studying the activity of lipoxygenase enzymes in 
polymorphonuclear leukocytes, macrophages, eosinophils, 
and mast cells. 
The enzyme, 5-lipoxygenase, converts arachidonic 
acid to 5-hydroperoxyeicosatetraenoic acid, which then 
is converted to the corresponding 5-hydroxyacid or to a 
family of compounds containing a conjugated triene 
structure, the leukotrienes: LTA4 , LTB4 , LTC4 , LTD4 and 
LTE4 . LTB4 appears to be important in inflammatory 
conditions; it is a powerful chemoattractant of 
polymorphonuclear white blood cells and promotes the 
transvenular movement of white cells and fluid 
(102,103) .. LTB4 also mobilizes calcium in 
polymorphonuclear leukocytes and induces the discharge 
of lysosomal contents and the formation of superoxides. 
The peptide-containing leukotrienes LTC4 , LTD4, and LTE4 
collectively account for the biological activity of 
slow-reacting anaphylaxic substances and are major 
mediators of the bronchial contraction observed in 
allergen response (102,103). 
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Eicosanoids are not stored in cells, but are 
released immediately after biosynthesis (94). Many 
eicosanoids are biologically active and act locally in 
the immediate microenvironment as cellular messengers. 
Frequently, they function to amplify or inhibit other 
biological responses~ such as the action of a 
hormone (94). The eicosanoids also appear to be 
physiologic and pathologic mediators in a variety of 
clinical conditions, such as inflammation, immune 
responses, thrombosis~ control of tissue perfusion, and 
atherosclerotic cardiovascular disease (94,102,103). 
Pharmacol 0.9 i cal and Di eta,,..y Modulations .9.D · !.b§ 
Biosy_othesis of Eicosanoids 
It has been apparent for many years that numerous 
clinically important diseases, such as cardiovascular 
disease, are associated with severe alterations in 
eicosanoid metabolism (98). Because the active 
eicosanoids are rapidly inactivated by subsequent 
metabolism~ the speed cf the rate-limiting biosynthetic 
reaction can easily influence the steady-state level of 
active eicosanoid and its pathophysiological impact 
(99). Many successful therapeutic (Figure 7) and 
dietary interventions in eicosanoid metabolism have been 
established during the past three decades (104). 
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Meff\brane phosphol ipids 
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Figure 7. Effect of drugs on eicosanoid ( prostanoid and 
leukotriene) biosynthesis. Adapted from: 
Moore, P. K., 1985 ( 104). 
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Pharmacological Modulation 
The most important group of drugs which prevent 
phospholipase A2 activity are the corticosteroids 
<Figure 7). They are extremely valuable drugs, but have 
several harmful side effects, including peptic ulcer, 
osteoporosis and a generalized increase in 
susceptibility to infection (104). Corticosteroids exert 
most of their anti-inflammatory action by indirectly 
preventing phospholipase activity, as the general action 
of all steroids, and thereby stop the formation of 
inflammatory prostanoids and leukotrienes (104). Three 
groups of investigators (105-107) demonstrated that 
glucocorticoids induce synthesis and release of 
antiphospholipase proteins (macrocortin, lipomodulin, 
renocortin), thereby inhibiting the phospholipase Pr2. 
activity. 
Drugs which inhibit cyclooxygenase enzyme 
activity are usually referred to as non-steroidal anti-
inflammatory drugs CNSAID> (Figure 7). Aspirin 
(acetylsalicylate) is the prototype of all NSAID~ and 
was reported by the Reverend Edmund Stone (104) of the 
Royal Society in 1763. The elegant experiments of Roth 
and Siok (108) elucidated how aspirin covalently 
acetylates and inactivates a serine at the active site 
of cyclooxygenase in all type of cells. Another often 
used NSAID, acetaminophen (paracetamol), is a potent 
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antipyretic and analgesic agent, but it is more active 
on brain cyclooxygenase than on peripheral tissues 
( 109) . 
Aspirin has been used in clinical trials to treat 
patients with thrombotic disorders. In two randomized 
trials of large doses of aspirin in patients with 
transient cerebral ischemic attacks~ aspirin 
significantly lowered the incidence of stroke or death 
by 42 and 31 percent, respectively (110). In another 
study (111) of 1266 veterans with unstable angina~ 
aspirin reduced by 51 percent the rate of infarction or 
cardiac death in treated patients. The most frequently 
observed side effects of NSAID are ulceration and 
bleeding from the gut, renal damage and 
bronchoconstriction (104). Since prostanoids formed 
naturally in the body prevent formation of 
gastrointestinal ulcers, dilate the renal vasculature 
(thus protecting the kidney from being damaged by 
ischemia) and dilate the airways, it has been proposed 
that all of these side effects are due to inhibition of 
prostanoid biosynthesis (112,113). 
Dietar~ Modulation 
The discovery that Greenland Eskimos have a low 
incidence of myocardial infarction and ischemic heart 
disease prompted several studies of the effect of 
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dietary fat on polyenoic acid metabolism and the 
beneficial effects of such diets on cardiovascular 
physiology. Several investigations suggested that 
subjects whose diet consisted of fish as the major 
source of nutrients had a low risk of cardiovascular 
disease (82,114-116). 
Fish fats are rich in docosahexaenoic acid (DHA, 
22:6(.()3) !I docosapentaenoic acid <DPA!I 22:5W3) !I and EPA 
(117). These polyenoic acids, added exogenously or 
rel eased .LIJ .Y.i.Y.9 at the cellular 1 evel may induce 
inhibition of fatty acid metabolism or offer some 
beneficial effect against the risks of cardiovascular 
disease in several ways. First, they may exert their 
effect through vasoactive metabolites generated by 
cyclooxygenase and lipoxygenase pathways. For instance!! 
formation of a potent prostacyclin (PGI3) and not so 
potent thrombm~ane (TXA3) by conversion of EPA could 
provide antithrombotic effects (117). 
A second mechanism to explain the beneficial effect 
of polyenoic acids is the generation of cyclooxygenase 
inhibitors through conversion of the substrate by 
lipoxygenase. DHA!I for example, has been shown to form 
two different hydroxy acids by platelet lipoxygenase 
(118). Several recent studies have suggested that the 
hydroperoxy acids of polyenoic acids are potent 
inhibitors of platelet function (119-·121). If the 
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hydroperoxy acids of EPA, DHA and DPA are potent 
inhibitors of platelet function, then the release and 
metabolism of these fatty acids in sufficient quantity 
may offer protection against the contribution of 
platelets to thrombotic disease. 
Finally, all of these fatty acids may co-exist in 
membrane phospholipids. Simultaneous release of EPA, DHA 
and DPA may inhibit significantly the conversion of 
AA, since all four fatty acids compete for the available 
heme sites of cyclooxygenase instead of just one, even 
though some of these fatty acids are poor substrates for 
the enzyme. In conclusion, if sufficient quantities of 
these fatty acids are incorporated, released and 
metabolized by the cells, the fatty acids by themselves 
or through their metabolites may exert inhibitory 
effects and thereby alter AA metabolism. 
Supplemental methionine has been shown to raise SAM 
concentration in the liver of rats (1). Since SAM has 
been proved to be an analgesia and a cyclooxygenase 
inhibitor, it would therefore mimic the action of 
aspirin in lowering the prostanoid formation and 
preventing cardiovascular diseases in humans. Thus, this 
investigation set forth to elucidate the effect of 
supplemental methionine upon the cyclooxygenase activity 
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and upon the incorporation of long chain polyunsaturated 




General Outline of Research 
Based on previous investigations and the literature 
evidence cited earlier, this study was initiated to 
assess the effect of methionine-supplemented versus 
cysteine-supplemented diets upon the catabolism and 
uptake of long chain polyunsaturated fatty acids--
arachidonic acid CAA> and eicosapentaenoic acid <EPA>. 
Two separate experiments were conducted. In one, [1- 14CJ 
AA in corn oil was administered by stomach tube to each 
animal before sacrificing. In the second experiment, 
[1- 14CJ EPA was used instead of [1-14CJ AA. In both 
experiments, cyclooxygenase enzyme activity in rat liver 
microsomes was measured. Radioactive 
14C-phosphatidylinositol fractions in various tissue 
lipids were also quantitated by measuring radioactivity 
using Beckman LS-100C Liquid Scintillation system 
(Beckman Instruments, Inc., Irvine, CA). 
Finally, to elucidate the finding of organ 
specificity from preliminary study with respect to the 
uptake of AA and EPA into phosphatidylinositol fraction, 
the activities of brain and liver fatty acyl-CoA 
synthetases were measured to obtain apparent 
Michaelis-Menten Constants (Km) for AA and EPA. 
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Dietary Modulation 
For each of the two experiments, three groups of 15 
male Sprague-Dawley rats were randomly assigned and 
housed individually in wire bottom stainless steel 
cages. The animals were fed one of three prepared diets 
for 17 days. Whittle and Smith (122) demonstrated 
that metabolic alterations would be detected within a 
period of two weeks when rats were fed the diets shown 
in Table 1. 
All diets contained 15 percent casein and 0.02 
percent inorganic sulfate. One group of animals was fed 
a diet supplemented with 0.505 percent cysteine, while a 
second group was fed a diet supplemented with 0.625 
percent methionine. A control group was fed 
unsupplemented diets. Diet was given ad libitum and tap 
water were freely available to all animals. 
The rats used to study the apparent Km for AA and 
EPA of tissue fatty acyl-CoA synthetases were fed 
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!Nutritional Biochemicals Corporation~ Cleveland, 
Ohio. 
2Crisco, Procter and Gamble, Cincinnati, Ohio. 
3Mazola, Best Foods, Englewood Cliffs, New Je,,.sey. 
41.34g equals in mg: 92.8 MgC03, 207.0 NaCl, 336.0 
KCl, 636. 0 KI-IZ.:'04, 61. 5 FeP04. 2H20, O. 2 KI, 0. 3 NaF, 1. 8 
AlK(S04)2.12H20, 2.1 Cu(C2H302).H20, 1.2 MnC12.6H20. 
51\lutritional Biochemicals Corporation, Cleveland, 
Ohio. Vitamin Diet Fortification Mixture formulated to 
supply the following amounts of vitamins (g/kg vitamin 
premix): thiamin hydrochloride 1.0, riboflavin 1.0, 
niacin 4.5, p-amino-benzoic acid 5.0, calcium 
pantothenate 3.0, pyridoxine hydrochloride 1.0, ascorbic 
acid 45.0, inositol 5.0, choline chloride 75.0, 
menadione 2.25, biotin 0.020, folic acid 0.090, vitamin 
B12 0.00135, -tocopherol 5.0, vitamin A 9 x 105 units, 
vitamin D 1 ~·: 105 units, and sufficient glucose to make 
1 kg. 
6Alphacel, Nutritional Biochemicals Corporation, 
Cleveland, Ohio. 
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Pregaration §D~ Administration gf Radioactive!§§! 
Sol Llti ons 
A mi ~-:ture of 1. 18 uCi [ 1-14C J AA and 20 mg AA 
(or 0.625 uCi C1-14CJ EPA and 25mg EPA) in 1/2 ml corn 
oil for each animal was prepared 30 minutes before 
using in each experiment. The test solution was mixed 
thoroughly and administered to the animals by stomach 
tube five hours before sacrificing. Respective diets 
and tap water were provided throughout the five hour 
period. 
Animal Sacrifice and Tissue PreRaration 
Rats were stunned by a blow to the back of the head 
and decapitated with sharp shears. The brain, heart, 
lung, kidney and spleen were removed quickly and frozen 
until analysis of the phosphatidylinositol fraction was 
performed. Immediately after excision of the liver, the 
whole tissue were placed in ice-cold 1.15% KCl buffer 
solution for homogenizing. A 1:4 (w/v) liver homogenate 
was carried out on ice using a Thomas glass tissue 
homogenizer (Arthur H. Thomas Co., Philadelphia, PA> 
with a motor-driven teflon pestle. 
PreRaration of Liver Microsorne 
Cyclooxygenase has been purified from bovine 
vesicular gland microsomes by Miyamoto et al. (123) and 
described as a microsomal complex of enzymes. Therefore, 
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a preparation of liver microsomal fraction is necessary 
for assay of this enzyme. Liver homogenate was 
centrifuged at 10,000 x g for 25 minutes at 4o, using a 
30 type rotor in a L5-50 Beckman centrifuge (Beckman 
Instruments, Inc., Spinco Division, Palo Alto, CA>. The 
resultant supernatant fluid was subsequently centrifuged 
at 100,000 x g for 60 minutes at 4o, using a 50-Ti type 
rotor in a L5-50 Beckman centrifuge (Beckman 
Instruments, Inc., Spinco Division, Palo Alto, CA>, to 
obtain the liver microsomal fraction. The mitochondria 
and nuclei were transferred into labeled vial and frozen 
until the phosphatidylinositol fraction analysis. 
The liver microsomal pellet was resuspended in 2ml 
of cold 100mM-Tris/HCl buffer to give a final protein 
concentration of 0.1-1 mg/ml in the enzyme assay 
mi:-: ture. 
Determination of C~cloox~genase Enz~me Activit~ 
Cyclooxygenase activity was measured by the 
thiobarbituric acid <TBA) color reaction of 
malonaldehyde (MDA> formed from the cyclooxygenase 
pathway (124). F'GG2 and PGH2 (or PGG3 and F'GH3), the 
products of the reaction from AA (or EPA>, give rise to 
MDA in the presence of heme and reduced glutathione 
(GSH) (125,126). The indirect measurement of MDA has 
been widely used to reflect the cyclooxygenase activity 
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in biological materials such as stimulated platelets 
(127). The TBA analysis has the advantage that the 
principal reactant, MDA, is a water-soluble substance 
formed or released upon heating the sample in an acid 
medium, and the intensity of color of the red pigment 
formed in the TBA reaction is so great that the method 
offers great sensitivity. 
The assay procedure was performed according to 
Boopathy and Balasubramanian (128) with slight 
modification. The assay mixture contained 1 ml of 200 
mM-Tris/HCl, pH 8.0, 0.2 ml of 50 mM-GSH, 0.2 ml of 50 
uM-hemoglobin, 3 ul of 0.5 mM-AA, 0.497 ml of distilled 
H20 and 0.1 ml of enzyme. The reaction was started by 
the addition of AA and terminated after one minute of 
incubation at 270 by the addition of 0.4 ml of 100'Y. 
(w/v) trichloroacetic acid (TCA) in 1 M-HCl. After 
thorough mixing, 0.4 ml of 1'Y. (w/v)-TBA solution was 
added and the mixture was heated in a boiling-water bath 
for 20 minutes. After cooling to room temperature, the 
final assay mixture was transferred to a centrifuge tube 
and briefly centrifuged at low speed ((1000 x g), using 
an International Model V, size 2 centrifuge with 241 
rotor (International Equipment Co., Boston, MA). The 
absorbance of the clear supernatant fluid was measured 
in a Beckman spectrophotometer at 532 nm. In the control 
reaction mixture, the cofactor hemoglobin was omitted at 
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the time of incubation and added after the addition of 
TCA. Alternative controls were run when AA or enzyme was 
added at the end of incubation period. 
One unit of enzyme activity was defined as one 
nmole of MDA formed/min. The amount of MDA formed was 
calculated from a standard curve of MDA obtained by 
periodate oxidation of 2-deoxyribose (129). 
The amount of protein in the liver microsome 
preparation was determined by a simplified method of 
quantitating protein using the biuret and phenol 
reagents as described by Ohnishi and Barr (130). The 
Biuret reagent was prepared as follows: 1.5 g of 
CuS04. 5H20 and 6. 0 g of NaKC4H4 06. 4HZJ were dissolved in 
approximate 500 ml of water. Then, 300 ml of freshly 
prepared, carbonate-free 10% Cw/v) NaOH (30 g NaOH 
dissolved in 300 ml of pre-boiled water) was added to 
the first mixture with constant stirring. The final 
mixture was diluted to one liter, which was called the 
"Biuret reagent". The "protein reagent" was further 
prepared by mixing the Biuret reagent with 2.3% Cw/v) 
Na2C03 (1:7, v/v). 
One-half ml of the liver microsomal protein was 
diluted with 4.5 ml of 0.5 N NaOH to obtain a range of 
0.1-0.5 mg protein in the sample. To 0.8 ml of the 
sample was added 3.2 ml of the protein reagent. The 
mixture was quickly vortexed and allowed to stand at 
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room temperature for 10 minutes. Then, 0.1 ml of 2 N 
Folin-Ciocatleau phenol reagent was added while the 
mixture was vortexed again. After the final mixture was 
set at room temperature for 30 minutes, the absorbance 
was measured at 750 nm against a blank. Bovine serum 
albumin (139.2 ug/0.8 ml) was used as the standard. The 
amount of protein present in the samples was calculated 
by comparing it with known amount of protein in the 
standard. The enzyme activity was expressed as 
unit/mg protein/minute. 
Tissue LiQid Extraction 
Lipids from brain, heart, lung, spleen, kidney, and 
liver mitochondria and nuclei fractions were extracted 
and purified by the method of Folch et al. (131). 
The excess fat and other materials of frozen tissue 
sample were removed completely. Tissue was weighed and 
recorded before extraction of lipids began. The tissue 
or tissue fraction (liver mitochondria and nuclei) was 
homogenized with 2:1 chloroform-methanol mixture (v/v) 
to a final dilution five-fold of the weight of tissue 
sample to obtain a maximal lipid extraction (131). 
For brain or tissues of similar consistency, a Bronwill 
Biosonik Sonicator <Bronwill Scientific, Rochester, NY> 
set at maximum power and maximum transducence was used 
to homogenize the tissue with the proper amount of 
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chloroform-methanol mixture. Tougher tissues such as 
heart were cut up with shears before sonicationu 
The homogenate was filtered through Whatman No. 1 
filter paper into a labeled vial and washed thoroughly 
with 5 ml chloroform-methanol. The upper layer was 
removed by aspiration and a small volume of the 
chloroform layer was removed also to ensure complete 
removal of the top layer. Subsequently, the vial was 
set under a fume hood until the chloroform was 
completely evaporated. The residue was resuspended in 
0.1 ml of chloroform. Quantitative analysis of 
radioactive phosphatidylinositol (PI> in the 
concentrated lipid extract was performed by thin layer 
chromatography (TLC) ( 132). 
Ana~~sis of Radioactive Phosghatidylinositol Fraction 
A silica gel G TLC plate (20 x 20 cm, thickness of 
gel-250 um) was first scraped so that a 1 cm clear 
margin of plate was produced along the sides and top of 
the plate. Two 2.5 cm wide lanes on both sides were 
then made parallel to the sides of the plate. The plate 
was activated in an oven at 1200 for one hour. As soon 
as the plate was completely cool, 0.01 ml of standard 
L-PI from bovine liver (Sigma Chemical Co., 
St. Louis, MO) was spotted about 1.5 cm from the bottom 
of the plate on both side lanes for reference, with 
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respect to migration of phosphatidylinositol fraction 
during ascending chromatography. Thereafter, 0.03 ml of 
the concentrated lipid extract was spotted as a narrow 
streak in the middle section and 1.5 cm from the bottom 
of the plate. The lipid was applied with a Hamilton 
microliter syringe (Alltech Associates, Inc., 
Deer f i e 1 d , IL) . 
Once six spotted plates were dried, they were 
immediately and carefully positioned, bottom end first, 
in a multiplate rack <American Scientific Products, 
Stone Mountain, GA). The rack was then placed in a 
closed, glass developing tank (27 x 7 x 27 cm) 
containing chloroform/methanol/glacial acetic acid/water 
(175:105:28:14, v/v in ml). The developing tank was 
saturated with the developing mixture vapor by 
inserting two pieces of Whatman No. 1 filter paper 
before rack insertion. The solvent was allowed to 
migrate to about 0.5 cm of the top of the plate. The 
time required for plate development was usually two 
hours. The plate was then removed from the tank and 
allowed to dry under a fume hood at room temperature. 
The plate was placed in a closed chamber containing 
crystals of iodine. Using iodine vapor as a detector, 
PI was identified against the reference standard. After 
about 20 minutes exposure to the vapor, narrow bands of 
phospholipids appeared as yellow stripes. After the 
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plate was taken out of the iodine chamber, the colored 
stripe representing the PI was scraped directly into a 
labelled vial. As soon as 10 ml of 2,5-diphenyloxazole 
(PPO) in toluene (12 g/L) was added and thoroughly 
mixed, the vial was placed in the liquid scintillation 
spectrometer for radioactive counting. The amount of 
radioactive PI was expressed as CPM/g wet tissue weight. 
B§§~Y gf Lon9 Chain Fatty AcyJ-CoA Synthetase 
The assay of long chain acyl-CoA synthetase was 
measured by a modification of the procedure of 
Tanaka et al. (133), which is based upon an isotopic 
assay. The rate of [1- 14C J arachidonoyl (or [1- 14C J 
eicosapentaenoyl) CoA formation from [1- 14C J AA (or 
[1- 14CJ EPA) was determined by measuring radioactivity 
in the aqueous phase after extraction of the unreacted 
C1- 14C J AA (or [1-14CJ EPA> from the assay mixture. 
Brain and liver homogenates were obtained by 
homogenizing tissues with four volumes of a buffer 
solution containing 0.5 M Tris/HCl, pH 8.0, 20 mM 
monobasic phosphate, and 5 mM 2-mercaptoethanol. The 
homogenate was subjected to centrifugation at 10,000 x g 
for- 25 minutes at 4o, using a 30 type rotor in a L5-50 
Beckman centrifuge (Beckman Instruments, Inc., 
Spinco Division, Palo Alto, CA). The supernatant fluid 
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was saved and kept in ice until the assay procedure 
began. 
A 0.4 ml assay mixture contained the following 
reagents: 0.08 ml of 0"5 M Tris-HCl, pH 8.0; 0.004 ml of 
0.5 M dithiothreitol; 0.03 ml of 2 M KCl; 0.04 ml of 
0.15 M MgCI2; 0.04 ml of 0.1 M adenosine triphosphate 
<ATP); 0.02 ml of 20 mM coenzyme A <CoA); 0.04 ml of 10 
mM potassium C 1-·14CJ AA (or [ 1-14C] EPA) (0. 2 Ci /mol), 
in 16 mM Triton X-100 <Sigma Chemical Co., St. Louis, 
MO); and 0.146 ml of enzyme (brain or liver 
supernatant). A mixture (0.38 ml) containing all 
ingredients except CoA was preincubated at 350 in a 
water bath (Eberbach Corp., Ann Arbor, MI) for one 
minute. The reaction was started by adding 0.02 ml of 
20 mM CoA. After incubation at 3~.o for two minutes, ·the 
reaction was terminated by adding 2.5 ml of a mixture 
containing isopropanol, n-heptane, and 1 M H2S04 
(40/10/1, v/v/v). Then, 1.5 ml of n-heptane and 1 ml of 
H20 were added and thorough I y mi ~·~ed; the mi ~·~ture was 
then transferred into a centrifuge tube for subsequent 
centrifugation at 1,000 x g for 10 minutes at room 
temperature. The upper layer, containing the unreacted 
[1- 14CJ AA (or [1-14CJ EPA), was removed by suction, 
while the lower layer (aqueous phase) was washed twice 
with 2 ml of n-heptane, each time discarding the upper 
layer. Then, a 1 ml sample of the lower layer was 
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assayed for radioactivity by scintillation counting with 
10 ml 2,5-diphenyloxazole <PPO) in toluene (12 g/L) and 
6 ml ethylene glycol monoethyl ether. 
One unit of acyl-CoA synthetase activity was 
defined as the amount which catalyzed the formation cf 
one uM of [1-14 CJ arachidonoyl CoA (or [1-14 CJ 
eicosapentaenoyl CoA) per minute under the assay 
conditions used. Enzyme protein was determined by the 
method of Ohnishi and Barr (130) with bovine serum 
albumin as a standard. The specific activity was 
expressed as uM/rng protein/minute" 
In order to calculate acyl-CoA synthetase apparent 
Km for AA or EPA, a series of diluted concentrations of 
the substrates was prepared by diluting the original 
substrate concentration C0.2 uM) with Triton X-100 to 
0.1, 0.04, 0.02 and 0.01 uM. A double reciprocal plot 
of activity versus substrate concentration for brain and 
liver acyl-CoA synthetases was plotted to obtain the 
apparent Kmu 
Statistics 
Experimental data were analyzed by using analysis 
of variance CANOVA). When F-tests were significant 
(p(0.05), comparisons were made using Duncan~s new 
multiple range test to determine which pairs of means 




Effect of Methionine-Su~~lemented Versus C~steine-
Su~~lemented Diets on C~cloox~genase Enz~me Activit~ la 
B@t Liver Microsomes 
The data in Table 2 show the units of 
cyclooxygenase activity of liver microsomes of rats fed 
the three diets. These data present a significant 
decrease in enzyme activity in the liver microsomes from 
rats fed the methionine-supplemented diet. The decrease 
in enzyme activity is significant when compared with 
that of rats fed the cysteine-supplemented diet, but it 
is not significant when compared with that of rats fed 
the control diet. There was a statistically significant 
difference in enzyme activity between cysteine-
supplemented and control groups with respect to the 
administration of [1-14C] AA. However, no statistically 
significant difference was observed in the enzyme 
activity between these two groups upon the 
administration of [1-14CJ EPA. Furthermore~ there was 
no significant difference in the the cyclooxygenase 
activity within any dietary group of animals with 
respect to the treatment of [1- 14C ] AA or [1- 14C J EPA. 
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TABLE 2 
Cyclooxygenase Activities in Rat Liver Microsomes 








C 1-·14C J AA1 [ 1-·14C J EPA1 
unit/min/mg protein 2 
85.9 + 16.3 (5) a 102.1 + 24.0 C5) 3ab 
119.0 + 26.2 (5) b 114.7 + 22.5 (5) b 
75.9 t. 19.9 (5) a 75.2 t. 6.1 (5) a 
1All animals were administered [1- 14CJ AA or 
[1- 14C J EPA in corn oil by stomach tube five hours prior 
to sacrifice. 
2Data are averages t. SEM eNpressed as unit of 
enzyme activity/min/mg of microsomal protein. 
3 Numbers in parentheses indicate number of animals 
per treatment. 
4Values in a column not followed by the same 
superscript are significantly different Cp<0.05). 
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Effect of Methionine-Sueelemented Versus C~steine-
Sueelemented Diets ueon the IncorRoration of C1- 14CJ AA 
or C1- 14C J EPA into !b~ Phosghatidylinositol Fraction of 
Various Tissues 
The data presented in Tables 3 through 6 show 
no statistically significant differences due to the diet 
regimen in the incorporation of C1- 14C J AA or [1- 14CJ 
EPA into the PI fraction of heart, lung, spleen and 
liver mitochondria and nuclei. The data in Tables 7 and 
8 demonstrate a significant difference of [1-14CJ EPA 
uptake into the PI fraction of brain and kidney between 
animals fed the methionine-supplemented diet and those 
fed the control diet. 
However, a statistically significant difference 
(p(0.005) was observed with respect to the incorporation 
of either C1- 14CJ AA or C1- 14C J EPA into the PI fraction 
of various tissues. The PI of heart tissue incorporated 
approximately three times more C1-14CJ EPA than C1-14CJ 
AA, whereas PI of spleen, brain, and kidney tissues took 
up nearly two times more C1- 14C J EPA than C1- 14CJ AA. 
On the contrary, PI fraction of liver mitochondria and 
nuclei incorporated about 1.5-fold more C1-t4CJ AA than 
C 1-~14CJ EPA. 
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TABLE 3 
The Incorporation of C1- 14C J AA and [1- 14C J EPA into 
Phosphatidylinositol Fraction of Heart Tissue of 





Supp l emented 
Methioninc=-
Supplemented 
Cl- 14C J AA 1 C1- 14C J EPA 1 
cpm/g of wet weigh t2 
540.5 + 165.7 (5) 3a 1707.3 + 385.0 (5) a 
520.4 + 100.7 (5) a 1653.2 + 314 . 0 (4) a 
632.2 ~ 110.5 (5) a 1846.0 ~ 518.0 (5) a 
1All animals were administered [1- 14C J AA or 
C 1-·- 14C J EPA in corn ai 1 by stomach tube five hours prior 
to sacrifice .. 
2Data are averages + SEM e~·:pressed as cpm/g of wet 
tissue weight. 
3Numbers in parentheses indicate number of animals 
per treatment . 
4Values in a column not followed by the same 
superscript are significantly different (p(0.05). 
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TABLE 4 
The Incorporation of C1-14 CJ AA and C1-14CJ EPA into 
Phosphatidylinositol Fraction of Lung Tissue of 








C 1-14CJ AAI C 1-·14C J EPA! 
cpm/g of wet weight 2 
468.6 + 159.0 (5) 3a 1121.1 + 295.2 (5) a 
418.1 + 172.5 (5) a 1130.0 + 294.5 (4) a 
400.9 t 50.6 (5) a 984.9 t 294.4 (5) a 
! All animals were administered C1-14CJ AA (or 
[ 1 ·- 14C J EPA in corn oi 1 by stomach tube five hours prior 
to sacrifice. 
2Data are averages + SEM e~-:pressed as cpm/g of wet 
tissue weight. 
3NLtmbers in parentheses indicate number o-f animals 
per treatment. 
4\ial ues in a column not fol 10"'1ed by the same 
superscript are significantly different (p(0.05). 
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TABLE 5 
The Incorporation of [1-14CJ AA and [1-14CJ EPA into 
Phosphatidylinositol Fraction of Spleen Tissue of 
Control, Cysteine-Supplemented, and 
Methionine-Supplemented Rats 
Animal Group C 1-14CJ AAI [ 1--14C J EPA1 
cpm/g of wet weight2 
Control 1309.0 + 124.0 (5)3a 2961.0 + 636.0 (5)a 
Cystei nE'·-· 
Supplemented 1252.0 + 135.0 (5)a 2378.0 + 584.0 (4)a 
Methionine--
Supplemented 1458.0 ~ 298.0 (5)a 2904.0 ~ 306.0 (5)a 
1All animals were administered [1·-14CJ AA or 
[1·-14CJ EPA in corn oil by stomach tube five hours prior 
to sacrifice. 
2Data are averages+ SEM eNpressed as cpm/g of wet 
tissue weight. 
~lumbers in parentheses indicate number of animals 
per treatment. 
4Values in a column not followed by the same 
superscript are significantly different (p(0.05). 
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TABLE 6 
The Incorporation of C1-14CJ AA and C1-14CJ EPA into 
Phosphatidylinositol Fraction of Liver Mitochondria 
and Nuclei of Control, Cysteine-Supplemented, and 
Methionine-Supplemented Rats 
Animal Group C 1-·14C J AAI C 1-14 C J EP,~1 
cpm/g of wet weight 2 
Control 417 .. 0 + B4 .. 5 (5) 3a 241 .. 4 + 54 .. 0 (5) a 
Cystei ne·-
Supplemented 348.8 + 81.9 (5) a 253.3 + 33.8 (4) a 
Meth ion inc;:~-
Supplemented 349.4 + 55.8 (5) a 240.0 + 48.7 (5) a 
1All animals were administered C1·- 14CJ AA or 
C1- 14CJ EPA in corn oil by stomach tube five hours prior 
to sacrifice .. 
2Data are averages + SEM e:·:pressed as cpm/g o·f wet 
tissue weight. 
31\lumbers in parentheses indicate number of animals 
per treatment. 
4Values in a column not followed by the same 
superscript are significantly different (p(0.05). 
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TABLE 7 
The Incorporation of [1-14C J AA and [1-14CJ EPA into 
Phosphatidylinositol Fraction of Brain Tissue of 
Control, Cysteine-Supplemented, and 
Methionine-Supplemented Rats 
Animal Group C 1-·14C J AA I C 1-14C J EPAI 
cpm/g of wet weight 2 
Contr-ol 597.0 + 50.0 (5) 3a 1285.4 + 138.3 (5) a 
Cysteine·-
Suppl emented 579.0 + 133 . 0 (5) a 1178.4 + 81.2 (4} ab 
Methionine-
Supplemented 559.4 t 74.1 (5} a 1054.2 t 177.0 (5} b 
1All animals were administer-ed [1- 14C J AA or 
[1- 14CJ EPA in corn oil by stomach tube five hours prior 
to sacrifice. 
2Data are averages + SEM e~-~pressed as cpm/g of wet 
tissue weight. 
31'-.lumbers in parentheses indicate number o-f animals 
per treatment. 
4Values in a column not followed by the same 
superscript are significantly different (p<0.05}. 
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TABLE 8 
The Incorporation of [1-14CJ AA and [1-14CJ EPA into 
Phosphatidylinositol Fraction of Kidney Tissue of 







Supp 1 ementE•d 
[ 1 ~-t4C J AA I [ 1-14C J EPA1 
cpm/g of wet weight 2 
365.0 + 53.7 (5) 3a 1172.6 + 187.5 (5) a 
370.8 + 109.4 (5) a 888.0 + 71.7 (4) b 
429.6 t 62.0 (5) a 801.4 t 113.5 (5) b 
1All animals were administered [1·- 14C J AA or 
[1- 14C J EPA in corn oil by stomach tube five hours prior 
to sacrifice. 
2Data are averages + SEM e}·~pressed as cpm/g of wet 
tissue weight. 
31'~umbers in parentheses indicate number of animals 
per treatment. 
4Values in a column not followed by the same 
superscript are significantly different (p(0.05). 
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The A~~arent Km Constants cf Brain and Liver Ac~l-CoA 
S~nthetases for Substrates--[1-14CJ AA and [1-14CJ EE6 
Lineweaver-Burk plots in Figures 8 and 9 were 
prepared under standard assay conditions to obtain the 
maximal acyl-CoA synthetase acti~ity. The apparent Km 
values for the rE"~action using either [1-14CJ AA er [1-
14CJ EPA as substrates were calculated from the graphs 
of Figures 8 and 9. In the reaction using [1-14CJ AA 
as a substrate~ the apparent Km cf brain and liver 
acyl-CoA synthetases for this substrate are 
apprmdmately 4;d0-B M and 2;d0-7 M~ respectively. 
In the case of [1-14CJ EPA~ the respective apparent Km 
of brain and liver acyl-CcA synthetases are about 
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Figure£. Typical Lineweaver-Burk (double-reciprdcal) 
plots of acyl-~ijA synthetase activity versus 
substrate ((1- CJ AA) concentration for 
the brain and liver . Acyl-CoA synthetase in 
the supernatant of . tissue homogenate was 
incubated for l minute with optimal 
concentrations of ATP 1ijnd CoA, and various concentrations of [1- CJ AA as indicated. 
Data points represent quadruplicate analyses 
of two animals. 
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Figure 9. Typical Lineweaver-Burk (double-reciprocal) 
plots of acyl-~ijA svnthetase activity versus · 
substrate ([1- CJ EPA) concentration f or the 
brain and liver . Acyl-CoA svnthetase in the 
supernatant of tissue homogenate was incubated 
for 1 minute with optimal concentrations of 
ATP
1
ijnd CoA, and various concentrations of 
[1- CJ EPA as indicated. Data points 




Cyclooxygenase activity (Table 2) was significantly 
decreased <p<0.05) in the liver microsomes from rats fed 
the methionine-supplemented diet. There was a 34 percent 
decrease in cyclooxygenase activity with methionine 
supplementation compared to cysteine supplementation. 
S-Adenosyl-methionine (SAM> has been shown to inhibit 
cyclooxygenase activity (64). Also, previous 
investigations in this laboratory (1) have shown that 
rats fed diets supplemented with methionine have a 
two-fold increase in their liver concentrations of SAM 
compared to those rats fed a diet supplemented with 
cysteine. It is reasonable to assume, therefore~ that 
the inhibition of cyclooxygenase activity reported in 
Table 2 is a reflection of the inhibition of 
cyclooxygenase activity, due to an increase in the 
·tissue concentration of SAM. 
SAM has been demonstrated to have analgesic and 
anti-inflammatory properties because of its action as an 
inhibitor of cyclooxygenase. Cyclooxygenase is a key 
enzyme required for the conversion of the long chain 
polyunsaturated fatty acids into the biologically active 
prostaglandins, prostacyclins and thromboxanes in all 
tissues. 
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Inhibition of cyclooxygenase activity is the basis 
for the anti-inflammatory action of most non-steroidal 
anti-inflammatory drugs (NSAIDs) such as aspirin. 
Because eicosanoids have been shown to have vascular and 
hemostatic actions, many studies have examined this 
possibility. In platelets, thromboxane A2 is a major 
cyclooxygenase product synthesized from arachidonic 
acid. Thromboxane A2 has highly potent vasoconstricting 
and platelet-aggregating effects--actions that are 
associated with diseases of the cardiovascular systems. 
Low doses of aspirin have been prescribed for patients 
with unstable angina, those who are stroke prone or 
those who are considered at risk for coronary occulsion. 
This investigation demonstrated that 0.625 percent 
supplementation of dietary methionine fed to rats did 
raise the liver tissue concentrations of SAM to a 
sufficient level to inhibit cyclooxygenase in rat liver 
microsomes, thereby possibly mimicing the action of 
low dose of aspirin upon the integrity of the 
cardiovascular system. Therefore, it is attractive to 
speculate that supplemental methionine might be 
beneficial to unstable angina, stroke-prcine and/or 
cardiac patients. Due to the analgesic properties of SAM 
(64), it is also attractive to speculate that a diet 
high in methionine might reduce symptoms in the chronic 
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pain patient and/or the muscle pain associated with a 
fever. 
The incorporation of long chain polyunsaturated 
fatty acids into phospholipids occurs rapidly and is 
maintained under a dynamic equilibrium. This was 
evidenced from the data obtained (Tables 3-8) following 
the administration cJf [1- 14C J AA and [1·- 14C J EF'A by 
stomach tube to rats that were sacrificed 5 hours lateru 
The radiolabeled long chain polyunsaturated fatty acids 
are metabolized through a sequence of eventsu First, 
C1- 14C J AA or C1-14CJ EPA is incorporated more rapidly 
into the 2-position of phospholipids than into the 
1-position of phospholipids or triglycerides during 
fatty acid incorporation into chylomicrons in the 
intestinal mucosa (135). Then, the labeled 
phospholipids are removed from the hepato-circulation by 
selected regions of cells and become the metabolic pool 
for the synthesis of tissue phospholipids. 
From the findings of this study, rat spleen tissue 
incorporated the greatest amount. of C1- 14C J AA or 
C1- 14CJ EPA into the phosphatidylinositol fraction 
(Table 5) compared to all the other tissue investigated. 
Heart tissue (Table 3) incorporated the second most, 
whereas phosphatidylinositol of the liver mitochondria 
and nuclei (Table 6) incorporated the last. The spleen 
removes products of red-cell degradation and other 
7 ..... .. ::. 
foreign matter through phagocytosis by macrophages; 
C1-14C J AA or [1-14CJ EPA might be recognized as a 
foreign substance by macrophages of the spleen. 
Consequently the spleen would have the highest quantity 
of the radiolabeled phosphatidylinositol. 
The heart has been reported as one of the most 
responsive tissues to changes in dietary polyunsaturated 
fatty acids, especially those of 20 and 22 carbon chain 
lengths (136). Results of this study could probably 
explain the relative high uptake of AA and EPA into the 
phosphatidylinositol fraction of heart tissue lipid. 
The liver is the primary organ for degradation of 
all substances. The removal and reutilization of the 
remaining labeled long chain fatty acids would result in 
the least amount of labeled phosphatidylinositol in 
liver mitochondria and nuclei fractions. 
Based upon the cyclooxygenase data, it would be 
reasonable to assume that, if SAM inhibits 
cyclooxygenase and if phosphatidylinositol is the 
storage form of the C-20 polyunsaturated fatty acids, 
the phosphatidylinositol fraction from rats fed the 
methionine-supplemented diets would contain the highest 
level of radioactivity. However, in heart, lung, spleen 
and particulate fractions of liver evaluated for 
phosphatidylinositol radioactivity <Tables 3-6), there 
was no difference in the specific activity of 
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phosphatidylinositol among rats fed the control, 
cysteine-supplemented or methionine-supplemented dietsa 
Furthermore, the observations of phosphatidylinositol 
radioactivity of brain and kidney tissues of rats 
administered C1-14 CJ EPA (Tables 7 and 8) demonstrated 
different phenomena. The specific activity of brain 
phosphatidylinositol of rats fed control diet was 
significantly higher than that of rats fed methionine-
supplemented diet and was not significantly different 
from that of rats fed cysteine-supplemented diet 
(Table 7). On the other hand, phosphatidylinositol 
radioactivity in kidney tissue of rats fed control diet 
(Table 8) was significantly higher than those of rats 
fed both cysteine-supplemented and methionine-
supplemented diets. The reason for these phenomena 
remains to be elucidateda 
Moreover, there are other enzymes governing the 
release and metabolism of long chain fatty acids in 
tissue phospholipids that need to be considered. These 
include phospholipase A2, fatty acyl-CoA synthetase, 
acyl-CoA: lysophosphatide acyl transferase, acyl-CoA 
hydrolase and lysophospholipase. 
A comparison of data in Tables 3-8 indicates that 
the heart tissue incorporated approximately three times 
as much [1-·14 CJ EPA into the phosphatidylinositol 
fraction as [1·- 14C] AA. A lesser amount was incorporated 
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by the brain, lung, kidney and spleen tissues. In 
contrast, however, the particulate fraction of liver 
incorporated almost twice as much C1-14CJ AA into its 
phosphatidylinositol as it did C1-14CJ EPA. 
In order to provide a partial enzymatic explanation 
for differences in the incorporation of [1- 14C J EPA and 
C1-14CJ AA into phosphatidylinositol in liver and in 
other tissues, the apparent Km of fatty acyl-CoA 
synthetase was determined for both C1-14CJ AA and 
C1- 14CJ EPA in liver and brain. The results, in Figures 
8 and 9, demonstrate that the apparent Km for AA is 
4:·: 10-8 M in the brain and 2x 10--7 M in the 1 i ver, ~'llhi 1 e 
the ci.pparent Km for EPA is 2. 8~d 0-B M in the brain and 
3.3x10-7 Min the liver. The apprm:imate five-fold 
increase in the apparent Kms for EPA and AA in liver 
tissue compared to brain tissue would explain the 
decrease in specific activity of liver 
phosphatidylinositol compared to brain 
phosphatidylinositol. In addition~ the ratio between the 
apparent Kms for EPA and AA is 0.7 in the brain and 1.65 
in the liver. Thus the difference in Km between EPA and 
AA in the liver and brain tissues could explain the 
preferential incorporation of EPA into brain tissue 
phosphatidylinositol and AA into liver tissue 
phosphatidylinositol. However, the observation that the 
Vmax of acyl-CoA synthetase, Figures 8 and 9, for AA and 
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EPA is approximately five-fold higher in the liver 
tissue than in the brain tissue would tend to offset the 
effect of the higher apparent Km in the liver tissue~ if 
both tissues contained saturating levels of the fatty 
acids. Thus it appears that the physiological 
concentration of long chain polyunsaturated fatty acids 
is not sufficient to saturate the fatty acyl-CoA 
synthetase and that the acylation and subsequent 
incorporation of these fatty acids into 





The test hypothesis of this investigation was that 
methionine-supplemented diets could possibly interfere 
with the metabolism of polyunsaturated fatty acids, 
thereby altering the biosynthesis of the active 
metabolites, prostanoids, and the profiles of tissue 
phospholipids. The postulated mechanism of action for 
this dietary regimen would be to increase the tissue 
concentration of the active methyl donor, 
S-Adenosyl-methionine (SAM) which is also called an 
activated methionine. SAM is a potent inhibitor 
of the cycloaxygenase enzyme which is important for the 
synthesis of biologically active prostanoids. 
The results demonstrated that liver microsomes from 
rats fed the methionine-supplemented diet had a 
statistically significant decrease in cyclaoxygenase 
activity. However, metabolic regulation of the 
polyunsaturated fatty acids metabolism is controlled by 
a host of enzymes and in a dynamic equilibrium state. 
Measurement of the incorporation of eicosapentaenoic and 
arachidonic acids into the phosphatidylinositol fraction 
of rat tissues demonstrated no difference among the rats 
fed the control, cysteine-supplemented, and methionine-
supplemented diets. 
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The diff~rential incorporation of polyunsaturated 
fatty acids into phosphatidylinositol fraction by 
various tissues was partially explained by the apparent 
Kms for both arachidonic and eicosapentaenoic acids of 
fatty acyl-CoA synthetase in liver and brain tissues. 
Many other factors and enzymes which regulate the 
metabolism of phospholipids and the mechanism of action 
of SAM need to be elucidated in the future research on 
the beneficial effect of a methionine-supplemented diet. 
Therefore, one part of the null hypothesis is 
rejected and restated that supplemental methionine has 
an effect on the metabolism cf polyunsaturated fatty 
acids through the cycloaxygenase enzyme pathway. The 
other part of the null hypothesis that supplemental 
methionine has no effect on the incorporation of 
polyunsaturated fatty acids into tissue phospholipids 




1. LOO, G. 8,: SMITH, J. T. (1986) Down-r-egl\lation of 
r-at liver- B-adr-ener-gic r-eceptor-s by cysteine. Life 
Sci. 39, 1555-1561. 
2a CANTONI, G. L. (1953) SAM: A new intermediate 
for-med enzymatically fr-om L-methionine and ATP. J. 
Biol. Chem. 204, 403-416. 
3. CANTONI, G. L. & DURELL, J. (1957) Activation of 
methionine for- tr-ansmethylatian. II. The 
methionine-activating enzyme: StLtdies on the 
mechanism of the r-eaction. J. Biol. Chem. 225, 
1033-1048. 
4. MUDD, S. H. & CANTONI, G. L. (1958) Activation of 
methionine for- tr-ansmethylation. III. The 
methionine-activating enzyme of baker-~s yeast. J. 
Biol. Chem. 231, 481-492. 
5. LDMBARDINI, J. B., CHOU, T.-C. & TALALAY, P. (1973) 
Regulatar-y pr-aper-ties of adenosine tr-iphosphate-L-
methionine S-adenosyltr-ansfer-ase of r-at liver. 
Biochem. J. 135, 43-57. 
6. MUDD, S. H. & CANTONI, G. L. (1964) Biological 
tr-ansmethylatian, methyl gr-oup neogenesis and other-
"one-car-bon" metabolic r-eactions dependent upon 
tetr-ahydr-ofolic acid. In: 11 Compr-ehensive 
Biochemistr-y 11 (Flor-kin, M. 8,: Stotz, E.H., eds), 15, 
pp 1-47, Elsevier-, Amsterdam. 
7. FINKELSTEIN, J. D. (1967) Methionine metabolism in 
mammals. Effects of age, diet, and hor-mones on 
thr-ee enzymes of the pathway in r-at tissl\es. Ar-ch. 
Biochem. Biophys. 122, 583-590. 
8. LOMBARDINI, J. B. & TALALAY, P. (1971) For-mation, 
functions and r-egulator-y impor-tance of S-adenosy-L-
methionine. Adv. Enzyme Regul. 9, 349-384. 
9. NATORI, Y. (1963) Studies on ethionine. VI. Se~·:-
dependent behavior- of methionine and ethionine in 
r-ats. J. Biel. Chem. 238, 2075-2080. 
10. PAN, F., CHANG, G.-G., LEE, S.-C. & TANG, M.-S. 
(1968) IndLtction of methionine adenasyltr-ansfer-ase 
in r-at liver by cor-ticoster-oids. Proc. Sac. Exptl. 
Biol. Med. 128, 611-616u 
81 
11 . BALDESSAF< IN I , F\. J. 8~ KOF' IN, I . J. < 1966) S-
ad enosyl -methionine in brain and other tissues. J. 
Neurochem. 13, 769-777. 
12. SALVATORE, F., UTILI, R., ZAPPIA, V. & SHAPIRO, S. 
K. (1971) Quantitative analysis o-f SAM 8~ SAH in 
animal tissues. Anal. Biochem. 41, 16-28. 
13. CANTONI, G. La (1965) S-adenosylmethionine-
revisited. In: "Transmethylation and Methionine 
Diosynthesis" (Shapiro, S. K. a~ Schlenk, F., eds) 
pp 21-32, University of Chicago Press, Chicago. 
14. SCHLENK, F. (1965) In: "Progress in the Chemistry 
of Organic Natural Products" (Zeichmeister, L., 
ed) pp 23-61, Springer-Verlag, Berlin. 
15. SPRINGER, W. R. & KOSHLAND, D. E., JR. (1977) 
Identification of a protein methyltransferase as 
the cheR gene product in the bacterial sensing 
system. Proc. Natl. Acad. Sci. U.S.A. 74, 533-537. 
16. KORT, E. N., GOY, M. F., LARSEN, S. H., & ADLER, J. 
(1975) Methylation of a membrane protein involved 
in bacterial chemotaxis. Proc. Natl. Acad. Sci. 
U.S.A. 72, 3939-3943. 
17. o~DEA, R. F., VIVEROS, O. H., AXELROD, J., 
ASWANIKUMAR, S., SCHIFFMANN, E. & COCCORAN, B. A. 
(1978) Rapid stimulation of protein 
carboxymethylation in leukocytes by a chemotactic 
peptide. Nature 272, 462-464. 
18. HIRATA, F. & AXELROD, J. (1980) Phospholipid 
methylation and biological signal transmission. 
Sci. 209, 1082-1090. 
19. KAWARADA, Y. & OKUHARA, E. (1986) Antibodies 
specific for methylated DNA elicited in rabbits 
recognize only a single strand region of DNA 
containing 7-methylguanine. Tohoku J. Exp. Med. 
149 !I 151 •H• 161 . 
20. PFOHL-LESZKDWICZ, A., HEBERT, E., SAINT-RUF, G., 
LENG, M. t!-< DIF<I-IEIMEF\, G. (1986) J.o .Y.!.tJ:.9 enzymatic 
methylation of DNA modified with the mutagenic 
amine: 3-N,N-acetoxyacetyl amino-4,6-
dimethyldipyrido-[1,2-a:3',2'-d] imidazole. Cancer 
Lett. 32, 65-71. 
E-32 
21. TABOR, H., TABOR, C. W. & ROSENTHAL, S. M. (1961) 
The biochemistry of the polyamines, spermidine and 
spermine. Ann. Rev. Biochem. 30, 579-604. 
22. ZAPPIA, V., CARTENI-FARINA, M. & GALLETTI, P. 
(1977) S-adenosylmethionine and polyamine 
bi osynthesi s in human prostate. In: 11 Biochemistry 
of S-adenosylmethionine" (Salvatore, F., Borek, E., 
Zappia, V., Williams-Ashman, H. G. & Schlenk, F., 
eds) pp 473-492, Columbia University Press, New 
York. 
23. NISHIMURA, S., TAYA, Y., KUCHINO, Y. & OHASHI, z. 
(1974) Enzymatic synthesis of 3-(3-amino-3-
carboxypropyl) uridine in Escherichia Coli 
phenylalanine transfer RNA: Transfer of the 3-
amino-3-carboxyprcpyl group from S-
adenosylmethionine. Biochern. Biophys. Res. Comm. 
57, 702-708. 
24. NISHIMURA, S. (1977) Characterization & enzymatic 
synthesis of 3-(3-arnino-3-carboxypropyl) uridine in 
transfer RNA: Transfer of the 3-arnino-3-
carboxypropyl group from S-adenosylmethionine. In: 
"Biochemistry o·f S-adenosyl methionine 11 (Sal vat ore, 
F., Borek, E., Zappia, V., Williams-Ashman, H. G. 8( 
Schlenk, F., eds) pp 510-520, Columbia University 
Press, New York. 
25. STONE, G. L. & EISENBERG, M. A. (1975) Purification 
and properties of 7,8-diaminopelargonic acid 
amidotransferase. J. Biol. Chem. 250, 4029-4036. 
26. STONE, G. L. & EISENBERG, M. A. (1975) Biosynthesis 
of 7,8-diaminopelargonic acid and SAM. J. Biol. 
Chem. 250, 4037-4043. 
27. RUDIGER, H. & JAENICKE, L. (1969) On the role of S-
adenosylmethionine in the vitamin B12 dependent 
methionine biosynthesis. Eur. J. Biochem. 10, 557-
560. 
28. KNAPPE, J. & SCHMITT, T. (1976) A novel reaction of 
S-adenosylmethionine correlated with the activation 
of pyruvate forrnate-lyase. Biochem. Biophys. Res. 
Commun. 71, 1110-1117. 
29. JENCKS, D. A. & MATTHEWS, R. G. (1987) Allosteric 
inhibition of methylene tetrahydrofolate reductase 
by S-adenosylrnethionine. J. Biol. Chern. 262, 2485-
2493. 
83 
30. STAVRIANAPOULOS, J. G., GAMBINO-GIUFFRIDA, A. & 
CHARGAFF, E. (1976) Ribonuclease Hof calf thymus: 
Substrate specificity, activation, and inhibition. 
Nat. Acad. Sci. U.S.A. 73, 1087-1091. 
31. WALKER, R. D. & DUERRE, J. A. (1975) S-
adenosylhomocysteine metabolism in various species. 
Can. J. Biochem. 53, 312-319. 
32. CORTESE, R., PERFETTO, E., ARCARI, P., PROTA, G. & 
SALVATORE, F. (1974) Formation of uric acid from S-
adenosylhomocysteine in rat liver. Int. J. 
Biochem. 5, 535-545. 
33. FI N~(ELSTE IN, J. D II 8,: MART IN. J . J. < 1986) 
Methionine metabolism in mammals. J. Biol. Chem. 
261, 1582-1587. 
34. BALDESSAFi:INI, R. J. (1975) Bioligical 
transmethylation involving SAM: Development of 
assay methods and implications for neuropsychiatry. 
Int. F<ev. Neurobiol. 18, 41-67. 
35. AXELROD, J. (1962) The enzymatic N-methylation of 
serotonin and other amines. J. Pharmacol. Exp. 
Ther. 138, 28-33. 
36. ANDREOLI, V. M. & MAFFEI, F. (1975) Blood-Levels of 
S-Adenosylmethionine in Schizophrenia. Lancet, ii, 
922. 
37. COHEN, C. K., DUNNER, D. & AXELROD, J. (1970) 
Reduced catechol-0-methyltransferase activity in 
red blood cells of women with primary affective 
disorder. Sci. 170, 1323-1324. 
38. STRAMENTINOLI, G. (1985) SAM as a drug. In: 
11 E<iological Methylation and Drug Design" 
<Borchardt, R. T., Creveling, C. R. & Ueland, P. 
M., eds) pp 315-326, Humana Press, Cliffon, New 
Jersey. 
39. AGNOLI, A., RUGGIERI, S., CERONE, G., ALOISI, P., 
BALDASSARRE, M. & STRAMENTINOLI, G. (1977) In: 
"Depressive Disorders 11 (Garattini, S., ed) pp 447-
458, F. K. Schattauer Verlag, Stuttgart-New York. 
40. SCARZELLA, R. (1977) VI World Congress of 
Psychiatry, Honolulu, Commun. 
84 
41a CIMINO, Ma, VANTINI, G., ALGER!, s., CURATOLA, G., 
PEZZDLI, C. & STRAMENTINOLI, G. (1984) Age-related 
modification of dopaminergic and B-adrenergic 
receptor system: Restoration to normal activity by 
modifying membrane fluidity with S-
adenosylmethionine. Life Sci. 34, 2029-2039. 
42. HIRATA, F., VIVEROS, H. O., DILIBERTO, E. JR. & 
AXELROD, J. (1978) Identification and properties 
of two methyltransferases in conversion of 
phosphatidylethanolamine to phosphatidylcholine. 
Proc. Natl. Acacia Sci. U.S.A. 75, 1718-1721. 
43. WURTMAN, R. J., ROSE, C. M., MATTHYSSE, S., 
STEPHENSON, J. & BALDESSARINI, R. (1970) L-
dihydroxyphenylalanine: Effect on S-
adenosymethionine in braina Sci. 169, 395-397. 
44. CHALMERS, J. P., BALDESSARINI, R. J. & WURTMAN, R. 
J. (1971) Effects of L-dopa on norepinephrine 
metabolism in the brain. Proc. Natla Acad. Sci. USA 
68, 662-666. 
45. STRAMENTINOLI, G., CATTO, E. & ALGER!, S. (1980) 
Decrease of noradrenaline 0-methylation in rat 
brain induced by L-dopa. Reversal effect of SAM. 
Commun, Ja Pharm. Pharmacol. 32, 430-431. 
46. PAREDES, S. R., KOZICKI, P. A., FUKUDA, H., 
ROSSETTI, M. V. & BATLLE, A. M. C. (1987) SAM 
Its effect on aminolevulinate dehydratase and 
glutathionine in acute ethanol intoxication. 
Alcohol 4, 81-85. 
47. FED, F., PASCALE, R., GARCEA, R., DAINO, L., 
PIRISI, L., FRASSETTO, S., RUGGIU, M. E., DI 
PADDVA, C. & STRAMENTINOLI, G. (1986) Effect of the 
variations of SAM liver content on fat accumulation 
and ethanol metabolism in ethanol-intoxicated rats. 
Toxicol. Appl. Pharmacol. 83, 331-341. 
48. FIACCADDRI, F., DI PADOVA, C., GHINELLI, F., 
MAGNANI, Gn . P. 8{ SACCHINI, D. (1982) Effects of SAM 
on alcoholic liver disease humans. Hepatology 2, 
179. 
49. MICALI, M., CHITI, D. & BALESTRA, V. (1983) Double-
blind controlled clinical trial of SAM administered 
orally in chronic liver diseases. Curr. Therap. 
Res. 33, 1004-1013. 
85 
50. TSUKAMOTO, J., YOSHINAGA, T. & SANO, S. (1979) The 
role of zinc with special reference to the 
essential thiol groups in r-aminolevulinic acid 
dehydratase of bovine liver. Biochim. Biophys. Acta 
570, 167--·178. 
51. PAREDES, S. R., KOZICKI, P. A. & BATLLE, A. M. 
(1985) SAM a counter to lead intoxication? Camp. 
Biochern. Physiol. 82B, 751-757. 
52. IDEO, G. (1975) SAM: Livelli plasmatici nella 
cirrosi epatica e primirisultati sul suo impiego 
clinic! in epatalagia. Minerva Me~d. 66, 1571. 
53. MAZZANTI, R., ARCANGEL!, A., SALVADOR!, G., 
SMORLESI, C., DI PERRI, T., AUTERI, A., BOGGIANO, 
C. A., PIPPI, L., TOTI, M., BONCOMPAGNI, P., 
ANGIOLI, D., CAREMANI, M., MAGNOLFI, F., CAMARRI, 
E., MOTTA, R., FORCONI, A., CANDID! TOMASI, A., 
LOMI, M. & SOLD!, E. (1979) On the anti-steatosic 
effects of SAM in various chronic liver diseases 
(Multi-center Study). Curr. Therap. Res. 25, 25-34. 
54. STRAMENTINOLI, G., PEZZOLI, C. & GALLIE-KIENLE, M. 
(1979) Protective role of SAM against acetaminophen 
induced mortality and hepatic toxicity in mice. 
Biochem. Pharmac. 28, 3567-3571. 
55. MITCHELL, J. R., JOLLOW, D. J., POTTER, W. z., 
GILLETTE, J. R. & BRODIE, 8. 8. (1973) 
Acetaminophen-induced hepatic necrosis. IV. 
Protective role of glutathiane. J. Pharmacol. Exp. 
Med. 187, 211-21 7. 
56. PAREDES, S. R., JUKNAT DE GERALNIK, A. A., BATLLE, 
A. M. DEL C. ~< CONTI, H. A. (1985) Beneficial 
effect of SAM in lead intoxication. Another 
approach to clinical therapy. Int. J. Biochem. 
17, 625-629. 
57. STRAMENTINOLI, G., DI PADOVA, C., GUALANO, M., 
ROVAGNAT I , · F'. 8< GALL I --•:::r ENLE, M. < 1981 ) 
Ethynylestradiol-induced impairment of bile 
secretion in the rat: Protective effects of SAM and 
its implication in estrogen metabolism. 
Gastroenteralogy BO, 154-158. 
58. SCHREIBER, A. J., SUTHERLAND, E. & SIMON, F. R. 
(1982) Prevention of ethynylestradiol cholestasis 
by SAM: Possible role of phosphatidylcholine. 
Hepatology 2, 697. 
86 
59. DI PADOVA, Ca, TRITAPEPE, R., CAMMARERI, G., 
HUMPEL, M. & STRAMENTINOLI, G. (1982} SAM 
antagonized ethynylestradiol-induced bile 
cholesterol supersaturation in humans without 
modifying the estrogen plasma kinetics. 
Gastroenterology 82, 223-227. 
60a FREZZA, M., POZZATO, G., CHIESA, L., DI PADOVA, C. 
& STRAMENTINOLI, G. (1982} SAM-induced reversal of 
cholestasis of pregnancy in humans. Hepatology 
2, 178. 
61. KERN, F. JR., ERFLING, W. & SIMON, F. R. (1978) 
Effect of estrogens on the liver. Gastroenterology 
75, 512-522. 
62. STRAMENTINOLI, G., GUALANO, M. & ROVAGNATI, P. 
(1979) Influencce of SAM on irreversible binding 
of ethynylestradiol to rat liver microsomes, and 
its implication in bile secretion. Biochem. 
Pharmac. 28, 981-984. 
63. KAPPUS, H. & BOLT, H. M. (1974) Irreversible 
binding of ethynylestradiol metabolites to 
proteins. Lack of methylation by SAM. Harm. Metab. 
Res. 6, 333-334. 
64. GUALANO, M., STRAMENTINOLI, G. & BERTI, F. (1983) 
Anti-inflammatory activity of 8-adenosylmethionine: 
Interference with the eicosanoid system. Pharmacol. 
Res. Commun. 15, 683-696. 
65. GUALANO, M., BERTI, F. & STRAMENTINOLI, G. (1985) 
Anti-inflammatory activity of S-Adenosylmethionine 
in animal models: Possible interference with the 
eicosanoid system. Int. J. Tiss. Reac. 7, 41-46. 
66. CAPRETTO, C., CREMONA, C. & CANAPARO, L. (1985) A 
double-blind controlled study of S-
adenosylmethionine. V. Ibuprofen in gonarthrosis, 
coxarthrosis and spondylarthrosis. Clin. Trials J. 
22, 15-24. 
67. MARCOLONGO, R., GIORDANO, N., COLOMBO, B., CHERIE-
LIGNIERE, G., TODESCO, S., MAZZI, A., MATTARA, L., 
LEARDINI, G., PASSERI, M. & CUCINOTTA, D. (1985) 
Double-blind multicentre study of the activity of 
S-adenosylmethionine in hip and knee 
osteoarthritis. Curr. Ther. Res. 37, 82-94. 
87 
68. BURR, G. 0. & BURR, Ma Ma (1930) On the nature and 
role of the fatty acids essential in nutrition. J. 
Biol. Chem. 86, 587-621. 
69. l<LENI<, Ea (1965) In: "Advances in Lipid Research" 
(Paoletti, R. & Kritchevsky, D., eds) pp 1-23, 
Academic Press, New York, 
70. SAMUELSSON, B., GOLDYNE, M., GRANSTROM, E., 
HAMBERG, M., HAMMARSTROM, S. & MALMSTEN, Ca (1978) 
Prostaglandins and thromboxanes. Annua Rev. 
Biochema 47, 997-1029. 
71. 
7 ,., ..:.. . 
LANDS, W. Ea M. (1979) The biosynthesis and 
metabolism of prostaglandins. Ann. Rev. Physiol. 
41, 633-670a 
LANDS, W. E. M., LETELLIER, P. R., ROME, L. H. & 
VANDERHOEK, J. Y. < 1973) Inhibit i an of 
prostaglandin biosynthesis. Adv. Biosci. 9, 15-27. 
73. CULP, B. R. , TITUS, B. G. 8< LANDS, W. E. M. ( 1979) 
Inhibition of prostaglandin biosynthesis by 
eicosapentaenoic acid. Prostaglandins Med. 3, 269-
278. 
74. DKUYAMA, H. & LANDS, W. Ea M. (1972) Variable 
selectivities of acyl coenzyme A: Monoacyl-
glycerophosphate acyltransferases in rat liver. J. 
Biol. Chema 247, 1414-1423. 
75. OKUYAMA, H., YAMADA, K. & IKEZAWA, H. (1975) 
Acceptor concentration effect in the selectivity of 
acyl coenzyme A: 1-acylglycerylphosphorylcholine 
acyltransferase system in rat livera J. Biol. 
Chem. 250, 1710-1713. 
76. POSSMAYER, F., SCHERPHOF, G. L., DUBBELMAN, T. M. 
A. R., VAN GOLDE, La Ma G. & VAN DEENEN, L. L. M. 
(1969) Positional specificity of saturated and 
unsaturated fatty acids in phosphatidic acid from 
rat liver. Biochim. Biophys. Acta 176, 95-110. 
77. LANDS, W. E. M., INOUE, M., SUGIURA, Y. & OKUYAMA, 
H. (1982> Selective incorporation of poly-
unsaturated fatty acids into phosphatidylcholine by 
rat liver microsomes. J. Biol. Chem. 257, 14968-
14972a 
88 
78. LEE, A. G., EAST, J. M. & FROND, R. J. (1986) Are 
essential fatty acids essential for membrane 
function? Prag. Lipid Res. 25, 1-46. 
79. SUN, G. Y. & YAU, M. (1976) Incorporation of 1- 14C 
oleic acid and 1-14 C arachidonic acid into lipids 
in the subcellular fractions of mouse brain. J. 
Neurochem. 27, 87-92. 
80. SUN, G. Y. (1982) Metabolic turnover of 
arachidonoyl groups in brain membrane 
phosphoglycerides. In: 11 F'hospholipids in the 
Nervous System" (Horrocks, et al., eds), 1, pp 75-
89, Raven Press, New York. 
81. SUN, G. Y., SU, K. L., DER, 0. M. 8,: TANG, W. (1979) 
Enzymic regulation of arachidonate metabolism in 
brain membrane phosphoglycerides. Lipids 14, 229-
235. 
82. SIESS, W., ROTH, P., SCHERE, B., KURZMAN, I., 
BOHLING, B. & WEBER, P. C. (1980) Platelet membrane 
fatty acids, platelet aggregation and thromboxane 
formation during a mackerel diet. Lancet 1, 441-
444. 
83. PHILBRICK, D.-J., MAHADEVAPPA, V. G., ACKMAN, R. G. 
~,: HOLUB, B.' J. (1987) Ingestion of fish oil or a 
derived w-3 fatty acid concentrate containing 
eicosapentaenoic acid <EPA> affects fatty acid 
compositions of individual phospholipids of rat 
brain, sciatic nerve and retina. J. Nutr. 
117, 1663-1670. 
84. GALLI, C., TF<ZECIAK, H. I. ~,: PAOLETTI, R. < 1971 > 
Effects of dietary fatty acids on the fatty acid 
composition of brain ethanolamine phosphoglyceride: 
reciprocal replacement of w-6 and w-3 
polyunsaturated fatty acids. Biochim. Biophys. 
Acta 248, 449-454. 
85. LAMPTEY, M. S. & WALKER, B. L. (1976) A possible 
essential role for dietary linolenic acid in the 
development of the young rat. J. Nutr. 106, 86-93. 
86. FOOT, M., CRUZ, T. F. & CLANDININ, M. T. (1982) 
Influence of dietary fat on the lipid composition 
of rat brain synaptosomal and microsomal membranes. 
Biochem. J. 298, 631-640. 
87. SANDERS, T. A. Bn, MISTRY, M. & NAISMITH, D. J. 
(1984) The influence of a maternal diet rich in 
linoleic acid on brain and retinal docosahexaenoic 
acid in the rat. Br. J. Nutr. 51, 57-66. 
88. SANDERS, T. A. B., NAISMITH, Du J., HAINES, A. P. & 
VICKEF~S!I M. (1980) Cod liver oil, platelet fatty 
acids, and bleeding time. Lancet 2, 1189-1192. 
89. SANDERS, T. A. B., VICKERS, M. & HAINES, A. P. 
(1981) Effect on blood lipids and haemostasis of a 
.supplement of cod-liver oil, rich in 
eicosapentaenoic acids, in healthy young men. Clin. 
Sci. 61, 317-·324. 
90. GOODNIGHT, S. H. JR., HARRIS, Wu S. & CONNOR, W. E. 
(1981) The effects of dietary w-3 fatty acids on 
platelet composition and function in man: a 
prospective, controlled study. Blood 58, 880-885. 
91. BROX, J. H., KILLIE, J. E., GUNNES, S. & NORDOY, 
A. (1981) The effect of cod-liver oil and corn oil 
on platelets and vessel wall in man. Thrombosis 81. 
Hameostasis 46, 604-611. 
92. THORNGREN, M. & GUSTAFSON, A. (1981) Effects of 11-
week increase in dietary eicosapentaenoic acid on 
bleeding time, lipids, and platelet aggregation. 
Lancet 2, 1190-1193. 
93. MEAD, J. F., ALFIN-SLATER, R. B., HOWTON, D. R. & 
POPJAK, G. (1986) Prostaglandins, thromboxanes, and 
prostacycl ins. In: "Lipids: Chemistry, 
Biochemistry, & Nutrition'' (Mead, et al., eds) pp 
149-216, Plenum Press, New York and London. 
94. LANDS, W. E. M. & SAMUELSSON, B. (1968) 
Phospholipid precursors of prostaglandins. Biochim. 
Biophys. Acta 164, 426-429. 
95. HOKIN, L. E. (1968) Dynamic aspects of 
phospholipids during protein secretion. Internat. 
Rev. Cytol. 23, 187. 
96. MITCHELL, F<. H. (1975) Inositol phospholipids and 
cell surface receptor function. Biochim. Biophys. 
Acta 415, 81-147. 
90 
97. DAWSON, R. M. C. & IRVINE, R. F. (1978) Possible 
role of lysosomal phospholipases in inducing tissue 
prostaglandin synthesis, In: "Advances in 
Prostaglandin and Thromboxane Research'' (Galli, C., 
Galli, G. & Porcellati, G., eds) pp 47-54, Raven 
Press, New York. 
98. CANNON, P. J. (1984) Eicosanoids and the blood 
vessel wall. Circulation 70, 523-528. 
99. VANE, J. R., BUNTING, Sft & MONCADA, S. (1982) 
Prostacyclin in physiology and pathophysiology. In: 
11 International Review of E~·~per i mental Pathol ogy 11 
(Richter, G. W. & Epstein, M. A., eds), 23, pp 161-
207, Academic Press, New York. 
100. NEEDLEMAN, P., RAZ, A., MINKES, M. S., FERRENDELLI, 
J. A. & SPRECHER, H. (1979) Triene prostaglandins: 
prostacyclin and thromboxane biosynthesis and 
unique biological properties. Proc. Natl. Acad. 
Sci. U.S.A. 76, 944-948. 
101. GRYGLEWSKI, R. J., SALMON, J. A., UBATUBA, F. B., 
WEATHERLY, B. C., MONCADA, 8. & VANE. J. R. (1979) 
Effects of all-cis 5,8,11,14,17-eicosapentaenoic 
acid and PGH3 cm platelet aggregation. 
Prostaglandin 18, 453-478. 
102. SAMUELSSON, 8. (1983) Leukotrienes: Mediators of 
immediate hypersentivity reactions and 
inflammation. Sci. 220, 568-575. 
103. LEWIS, R. A. & AUSTEN, K. F. (1984) The 
biologically active leukotrienes. Biosynthesis, 
metabolism, receptors, functions and pharmacology. 
J. Clin. Invest. 73, 889-897. 
104. MOORE, P. K. (1985) Effect of drugs on arachidanic 
acid metabolism. In: 11 Prostanoids: Pharmacological, 
Physiological and Clinical Relevance'' (Moore, P. 
K., ed), 2, 41-67, Cambridge University Press, 
London. 
105. BLACKWELL, G. J., CARNUCCIO, R., DIROSA, M., 
FLOWER, R. J., PARENTE, L. & PERSICO, P. (1980) 
Macrocortin: A polypeptide causing the anti-
phospholipase effect of glucocarticoids. Nature 
287, 14·7-149. 
91 
106. CLOIX, J. F., COLARD, O., ROTHHUT, B. & RUSSO-
MARIE, F. (1983) Characterization and partial 
purification of ~renocortins~: Two polypeptides 
formed in renal cells causing the anti-
phospholipase-like action of glucocorticoids. Br. 
Pharmacol. 79, 313-321. 
107. HIRATA, F., SCHIFFMAN, W., VENKATASUBRAMANIAN, K., 
SALMON, D. & AXELROD, J. (1980) A phospholipase A2 
inhibitory protein in rabbit neutrophils induced by 
glucccorticoids. Proc. Natl. Acad. Sci. U.S.A. 77, 
2533-2536. 
108. ROTH, G. R. & SIOK, C. J. (1978) Acetylation of the 
NH2-terminal serine of the prostaglandin synthetase 
by aspirin. J. Biol. Chem. 253, 3782-3784. 
109. FLOWEF~, F~. J. 81. VANE, J. F~. ( 1972) Inhibition of 
prcstaglandin synthetase in brain explains the 
antipyretic activity of paracetamol (4-
acetaminophenol) Nature 240, 410-411. 
110. PRESCOTT, S. M. & MAJERUS, P. W. (1983) Drugs for 
the prevention of cardiovascular disease. In: 
"Prevention of Coronary Heart Disease" (Kaplan, N. 
M. & Stamler, J., eds) pp 147-160, W. B. Saunders, 
Co., Philadelphia. 
111. V.A. COOPERATIVE STUDY (1983) Protective effects of 
aspirin against acute myocardial infarction and 
death in men with unstable angina. N. Engl. J. Med. 
309, 396. 
112. FERREIRA, S. H. & VANE, J. R. (1974) New aspects of 
the mode of action of nonsteroid anti-inflammatory 
drugs. Ann. Rev. Pharmacol. 14, 57-73. 
113. HIGGS, G. A. ~,. VANE, J. F.:. (1983) Inhibition of 
cyclooxygenase and lipoxygenase. British Medical 
Bulletin 39, 265-270. 
114. DYEBERG, J. & BANG, H. O. (1979) Hemostatic 
function and platelet polyunsaturated fatty acids 
in Eskimos. Lancet 2, 433-435. 
115. BANG, H. 0., DYEBERG, J. 81. SINCLAIF~, H. M. < 1980) 
The composition of the Eskimo food in north western 
Greenland. Am. J. Clin. Nutr. 33, 2657-2661. 
92 
116. CULP, B. R., LANDS, W. E. M., LUCCHES, B. R., PITT, 
Fe. ~1. ROMSON, J. ( 1980) The effect of di etar-y 
supplementation of fish oil on exper-imental 
myocardial infar-ction. Pr-ostaglandins 20, 1021-
1031. 
117. GOODNIGHT, S. H., HARRIS, W. S., CONNOR, W. E. & 
ILLINGWORTH, D. R. ~1982) Polyunsatur-ated fatty 
acids, hyper-lipidemia, and thr-ombosis. 
Ar-ter-ioscler-osis 2, 87-113. 
118. AVELDANO, M. I. & SPRECHER, H. (1983) Synthesis of 
hydr-oxy fatty acids fr-om 4,7,10,13,16,19 (1-
14C) docosahexaenoic acid by human platelets. J. 
Biol. Chem. 258, 9339-9343. 
119. BILD, G. S., BHAT, S. G. ~'- AXELROD, B. ( 1978) 
Inhibition of aggr-egation of human platelets by 
8,15-dihydr-oper-oxides of 5,9,11,13-eicosatetr-aenoi~ 
and 9,11,13-eicosatr-ienoic acids. Pr-ostaglandins 
16!1 795-799 .. 
120. VERICEL, E. & LAGARDE, M. (1980) 15-
hydr-oper-oxyeicosatetr-aenoic acid inhibits human 
platelet aggr-egation. Lipids 15, 472-474 .. 
121 • AHA Fm NY, D. , SM I TH, J. B. ~1. SIL VEF.:, M. J . ( 1982) 
Regulation of arachidonate-induced platelet 
aggr-egation by the lipoxygenase pr-oduct, 12-
hydroper-oxyeicosatetraenoic acid. Biochim. 
Biophys. Acta 718, 193-200. 
122. WHITTLE, B. & SMITH, J. T. (1974) Effect of dietary 
sulfur- on taur-ine excr-etion by the r-at .. J. Nutr-. 
104, 666-670. 
123. MIYAMOTO, T., OGIND, N., YAMAMOTO, S. & HAYAISHI, 
0. (1976) Pur-ification of pr-ostagle.ndin 
endoperoxide synthetase fr-om bovine vesicular- gland 
micr-osomes. J .. Biol. Chem. 251, 2629-2636. 
124. HAMBERG, M. & SAMUELSSON, B. (1973) Detection and 
isolation of an endoper-oxide inter-mediate in 
prostaglandin biosynthesis. Pr-oc. Natl. Acad. Sci. 
U.S.A. 70, 899-903. 
125. HAMBERG, M. & SAMUELSSON, B. (1974) Prostaglandin 
endoper-oxides. Novel tr-ansfor-mations of ar-achidonic 
acid in human platelets. Proc. Natl. Acad. Sci. 
U.S.A. 71, 3400-3404. 
9 °':?' ·-· 
126. SHIMIZU, T., KONDO, K. & HAYAISHI, 0. (1981) Role 
of prostaglandin endoperoxides in the serum 
thiobarbituric acid reaction. Arch. Biochem. 
Biophys. 206, 271-276. 
127. HAMELIN, S. ST-J. & CHAN, A. C. (1983) Modulation 
of platelet thromboxane and malonaldehyde by 
dietary vitamin E and linaleate. Lipids 18, 267-
269. 
128. BOOPATHY, R. & BALASUBRAMANIAN, A. S. (1986) 
Purification and characterization of sheep platelet 
cyclooxygenase: Acetylation by aspirin prevents 
heme binding to the enzyme. Biochem. J. 239, 371-
377. 
129. WARAVDEKAR, V. S. & SASLAW, L. D. (1957) A method 
of estimation of 2-deoxyribose. Biochim. Biophys. 
Acta 24, 439. 
130. OHNISHI, S. T. & BARR, J. K. (1978) A simplified 
method of quantitating protein using the biuret and 
phenol reagents. Anal. Biochem. 86, 193-200. 
131. FOLCH, J., LEES, M. & STANLEY, H. S. (1956) A 
simple method for the isolation and purification of 
total lipids from animal tissues. J. Biol. Chem. 
226, 497-509. 
132. PARKER, F. & PETERSON, N. F. (1965) Quantitative 
analysis of phospholipids and phospholipid fatty 
acids from silica gel thin-layer chromatograms. 
J. Lipid Res. 6, 455-459. 
133. TANAKA, T., HOSAKA, K. & NUMA, S. (1981) Long-chain 
acyl-CoA synthetase from rat liver. Methods 
Enzyrnol. 71, 334-341. 
134. SNEDECOR, C. W. & COCHRAN, W. G. (1967) Statistical 
Methods, 6th ed., Iowa State University Press, 
Ames. 
135. HIGGINS, J. A. & GREEN, C. (1967) The entry of 
palmitic acid into rat liver cells. Biochem. J. 
104, 26p. 
94 
136. KRAMER, J. K. G.~ FARNWORTH~ E. R.~ THOMPSON~ B. K. 
& CORNER~ A. H. (1981) The effect of dietary fatty 
acids on the incidence of cardiac lesions and 
changes in the cardiac phospholipids in male rats. 
Prag. Lip. Res. 20~ 491-499. 
95 
VITA 
Mei Fung Chen, daughter of Yu Ming and Tong Chun 
Tai Chen, was born in Yinko, Taipei-Shan, Taiwan, on 
January 22, 1952. She was educated in the elementary 
school of Yinko, Taipei-Shan, Taiwan. She graduated from 
First-Girl High School, Taipei, Taiwan, in June 1969 and 
entered National Taiwan University, Taipei, Taiwan, in 
September 1969. She received a Bachelor of C • oc1ence 
degree with a major in Animal Husbandry in June 1973. 
In September 1973, she came to the United States. 
In January 1974, she started her graduate work at the 
University of Tennessee, Knoxville. She completed the 
requirements for a Master of Science degree with a major 
in Food Technology and Science in December 1975. 
In August 1975, she began to work at a meat 
processing company as a quality control supervisor. In 
February 1981, she had an opportunity to manage an 
oriental food and gift shop. In March 1986, she 
decided ta pursue doctorate degree in Nutrition and· Food 
Sciences at the University of Tennessee, Knoxville. She 
received the Doctor of Philosophy degree in August 1988. 
96 
